Progressive Myoclonic Epilepsy Type 11

Mendelian MONDO:0030034 Pathograph 32 Show in embeddings browser Progressive Myoclonus Epilepsy

Progressive myoclonic epilepsy type 11 (EPM11) is an autosomal dominant neurodevelopmental and epileptic disorder caused by heterozygous, almost always de novo, truncating variants in the last exon (exon 17) of SEMA6B, which encodes the class 6 transmembrane semaphorin 6B. Because these variants lie in the region where a premature stop codon escapes nonsense-mediated mRNA decay, the mutant transcript is stable and is predicted to yield a truncated protein that keeps its extracellular sema domain and transmembrane segment but lacks the intracellular domain through which class 6 semaphorins signal as receptors. Heterozygous truncating variants earlier in the gene occur in the general population, so simple haploinsufficiency is not the accepted mechanism; whether the truncated protein acts as a dominant negative, gains a toxic function, or adds to a partial loss of SEMA6B signalling is unresolved. Development is mildly delayed from infancy and seizures usually begin between about 1 and 6 years. In the classic presentation, action and cortical myoclonus, generalized tonic-clonic, atonic and absence seizures, cerebellar ataxia, pyramidal signs and cognitive and motor regression follow, with loss of independent walking and speech in the second decade. The same class of variants also produces developmental and epileptic encephalopathy without a recognized progressive myoclonic course and, less often, intellectual disability without epilepsy. This entry treats these presentations as one SEMA6B-related disease spectrum rather than as separate disorders, because they share the genotype and no genotype-phenotype correlation separates them.

Ask OpenScientist

Ask a research question about Progressive Myoclonic Epilepsy Type 11. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).

Submitting...

Do not include personal health information in your question. Questions and results are cached in your browser's local storage.

🏷

Classifications

Harrison's Part
NEUROLOGIC
👪

Inheritance

1
Autosomal Dominant (predominantly de novo) HP:0000006
A single heterozygous SEMA6B variant is sufficient to cause disease. Nearly all reported variants arose de novo, so recurrence within a family is unusual. Two exceptions are reported: a family with an adult-onset course and a missense variant shared by two affected siblings, and a family in which a splice-site variant outside the last exon segregated with epilepsy with marked incomplete penetrance. Penetrance of the classic exon 17 truncations cannot be judged because they are almost never inherited.
Autosomal dominant inheritance
Show evidence (5 references)
PMID:42696975 SUPPORT Human clinical
"segregating with autosomal dominant EPM1in a family exhibiting marked incomplete penetrance"
Dominant segregation with incomplete penetrance for a non-last-exon splice variant. The source abstract's "EPM1" is a typographical slip for EPM11, as its background sentence names EPM11 and SEMA6B.
CGGV:assertion_dc080017-6a01-4da0-a9f5-e89710890a4c-2025-01-21T170000.000Z SUPPORT Other
"SEMA6B | HGNC:10739 | progressive myoclonus epilepsy | MONDO:0020074 | AD | Definitive"
ClinGen's Epilepsy Gene Curation Expert Panel classifies SEMA6B in autosomal dominant progressive myoclonus epilepsy as Definitive. The record is filed against the parent class MONDO:0020074 rather than this MONDO term, so it is cited for the mode of inheritance and is not recorded as a gene-disease validity assertion for EPM11.
PMID:33798445 SUPPORT Human clinical
"Second, we independently validate SEMA6B as a dominant PME gene in two unrelated individuals."
Independent replication, in an exome study of unsolved progressive myoclonus epilepsy, that SEMA6B acts as a dominant disease gene.
+ 2 more references
?

Discussions and Knowledge Gaps

3
Do last-exon SEMA6B truncations cause disease by a dominant-negative effect on wild-type SEMA6B, by a new toxic function of the truncated protein, or by loss of function of the mutant allele that population data say is not sufficient on its own?
KNOWLEDGE GAP OPEN sema6b_truncation_mechanism
Attached to
pathophysiology#SEMA6B Last-Exon Truncating Variant Escaping NMD pathophysiology#Stable Truncated SEMA6B Lacking the Intracellular Domain pathophysiology#Disrupted SEMA6B-Plexin Signalling
The discovery study inferred a dominant-negative or gain-of-function mechanism from three facts: the variants escape decay, upstream truncating variants are tolerated, and zebrafish last-exon crispants were more severely affected than start-codon crispants. Later papers state the mechanism in different directions: one review calls it a toxic gain of function, while the neuronal study calls the tested variant loss-of-function and found that knockdown of wild-type Sema6b reproduced the spine defect. The truncated protein is overexpressed and mislocalized in transfected cells, which fits either retention of wild-type partners or a new activity. None of the experiments tested the variant at physiological heterozygous dosage in a mammalian neuron, and the zebrafish crispants were mosaic, so the field has a consistent observation (position matters) without a demonstrated mechanism. This is why functional_impact_category is UNKNOWN.
Proposed experiments
Heterozygous exon 17 truncation knock-in compared with a heterozygous null
sema6b_heterozygous_knockin_vs_null
Generate mice or human iPSC-derived cortical neurons heterozygous for a recurrent exon 17 truncation, and in parallel heterozygous and homozygous null alleles, then compare spine density, axon targeting, network excitability and, in mice, seizure susceptibility. Co-express wild-type and truncated SEMA6B to test whether the truncated protein retains wild-type SEMA6B or plexin-A2 intracellularly.
Would support
pathophysiology#Disrupted SEMA6B-Plexin Signalling
Supporting outcome
  • The heterozygous knock-in has a phenotype that the heterozygous null lacks, and the truncated protein retains wild-type SEMA6B or plexin-A2 away from the membrane, favouring a dominant-negative effect.
Refuting outcome
  • Heterozygous knock-in and heterozygous null neurons are indistinguishable, which would argue against a dominant mechanism of the truncated protein.
Show evidence (3 references)
PMID:32169168 SUPPORT Human clinical
"Collectively, these results indicate that the pathomechanism of truncating DNVs in the NMD(−) region of SEMA6B was most likely dominant-negative or gain-of-function, but not haploinsufficiency."
The discovery study's inference, which names two mechanisms without choosing between them.
PMID:36719163 SUPPORT BACKGROUND Human clinical
"The exon 17 is mainly involved, with truncating mutations causing the production of aberrant proteins with toxic gain of function."
A later clinical series states a toxic gain of function as if settled, without new functional data.
PMID:35604360 SUPPORT In vitro / ex vivo
"This study confirms that loss-of-function variants in the last exon confer pathogenicity and shows that missense mutations also exert deleterious effects."
The neuronal study describes the same variant class as loss-of-function, the opposite framing.
Are SEMA6B-related developmental and epileptic encephalopathy and intellectual disability without epilepsy the same disease as EPM11?
INTERPRETATION OPEN sema6b_spectrum_lump
Attached to
disease#Progressive Myoclonic Epilepsy Type 11
This entry lumps them. All presentations arise from the same heterozygous de novo variants, mostly the same exon 17 truncations, and recurrent variants appear in patients classed in different groups. No genotype correlates with the progressive myoclonic versus encephalopathy presentation, MONDO and OMIM carry only the EPM11 concept, and several patients first diagnosed with an encephalopathy later developed the progressive myoclonic course. Age at last examination may explain part of the difference, since progressive myoclonus usually becomes evident in the second decade. The lump should be revisited if a genotype-phenotype correlation emerges or if missense variants prove to cause a distinct disorder.
Show evidence (2 references)
PMID:36719163 SUPPORT Human clinical
"Moreover, by the revision of literature, severity does not clearly correlate with genotype, and patients with the same genetic alteration could present different phenotypes."
The same variant can produce different presentations, which argues for a single disease spectrum.
PMID:39419291 SUPPORT REVIEW SYNTHESIS Human clinical
"In conclusion, although SEMA6B has been associated with PME, it may actually cause a much broader phenotypic spectrum."
Systematic review conclusion that SEMA6B disease is a spectrum broader than PME.
What drives the regression in EPM11: ongoing neurodegeneration, the cumulative effect of seizures and myoclonus, or a developmental lesion that becomes symptomatic with age?
KNOWLEDGE GAP OPEN sema6b_progression_mechanism
Attached to
phenotypes#Developmental Regression phenotypes#Loss of Speech phenotypes#Spasticity
Patients lose motor and language skills, often in the second decade, yet brain MRI is normal in most and neither neuropathology nor a model has shown neuronal loss. One appraisal attributes motor regression partly to worsening myoclonus, and treating myoclonus improved gait in one patient, but cognitive regression and pyramidal signs have no explanation. These phenotypes are therefore left without a causal edge in this entry.
Show evidence (1 reference)
PMID:36719163 SUPPORT Human clinical
"Repeated MRIs (from the age of 3 to 25 years) were normal."
Normal serial imaging despite severe regression in one patient.
⚙

Pathophysiology

8
SEMA6B Last-Exon Truncating Variant Escaping NMD
Disease-causing variants are heterozygous nonsense and frameshift variants clustered in exon 17, the last exon of SEMA6B, where a premature stop codon does not trigger nonsense-mediated mRNA decay. In lymphoblastoid cells from an affected individual the mutant transcript was present at a level comparable to the wild-type transcript. Truncating variants upstream of this region, which would be degraded, are seen in the general population, and SEMA6B is tolerant of loss-of-function variation; the pathogenic variant class is therefore defined by its position, not by truncation as such.
Genetic context SEMA6B hgnc:10739 HUGO Gene Nomenclature Committee (hgnc) Relation: this genetic context concerns this gene This genetic context concerns SEMA6B (hgnc:10739). hgnc:10739 is a gene from the HUGO Gene Nomenclature Committee. variant_origin: DE_NOVO zygosity: HETEROZYGOUS functional_impact_category: UNKNOWN
Frameshift and nonsense variants in the nonsense-mediated decay escape region (exon 17). functional_impact_category is left UNKNOWN because dominant-negative, gain-of-function and loss-of-function readings of the truncated protein have each been proposed and none has been shown in a mammalian system; see the discussion sema6b_truncation_mechanism.
Downstream
Stable Truncated SEMA6B Lacking the Intracellular Domain
Show evidence (3 references)
PMID:32169168 SUPPORT Human clinical
"RNA analysis of lymphoblastoid cells established from an affected individual showed that the mutant allele escaped NMD, indicating stable production of the truncated protein."
Patient-derived cells show the mutant transcript escapes nonsense-mediated decay.
PMID:32169168 SUPPORT Human clinical
"Importantly, heterozygous truncating variants in the NMD(+) region of SEMA6B are observed in general populations, and SEMA6B is most likely loss-of-function tolerant."
Truncating variants that would be degraded are tolerated in the population, which argues against haploinsufficiency as the mechanism.
PMID:38091987 SUPPORT Human clinical
"The PTVesc-enriched genes included those with PTVescs previously described to cause dominant Mendelian disease (e.g., SEMA6B, PPM1D, and DAGLA)."
In 29,031 neurodevelopmental-disorder trios, de novo truncating variants in the decay-escape region of SEMA6B were significantly enriched, replicating the variant class independently of the discovery cohort.
Stable Truncated SEMA6B Lacking the Intracellular Domain
The exon 17 variants remove the intracellular domain while leaving the extracellular sema domain, plexin-semaphorin-integrin domain and transmembrane segment encoded. When one truncating variant was expressed in cultured cells, the truncated protein accumulated to higher levels than wild-type SEMA6B and failed to reach the plasma membrane, and a truncating variant tested in a second study was likewise mislocalized.
Downstream
Disrupted SEMA6B-Plexin Signalling
Show evidence (4 references)
PMID:32169168 SUPPORT Human clinical
"All four variants occurred in the last exon of SEMA6B and lead to truncation of the intracellular domain (ICD), the region closer to the C terminus than the transmembrane domain"
Locates the pathogenic truncations to the intracellular domain.
PMID:34017830 SUPPORT In vitro / ex vivo
"results in a truncated protein with remarkably increased expression compared to that of the wild type."
In transfected cells the truncated protein is produced and is more abundant than the wild-type protein.
PMID:34017830 SUPPORT In vitro / ex vivo
"The truncated protein presented more homogeneous and failed to locate in the plasma membrane."
The truncated protein does not reach the cell surface, where SEMA6B normally acts.
+ 1 more reference
Disrupted SEMA6B-Plexin Signalling
SEMA6B binds plexin-A2 and acts as a receptor whose intracellular domain carries reverse signalling into the cell; in chick commissural neurons a SEMA6B lacking that domain cannot substitute for the full-length protein. Disease variants alter SEMA6B binding to plexin-A2 in co-immunoprecipitation experiments. Whether the truncated protein blocks signalling by the wild-type protein, signals aberrantly, or simply fails to signal is not established, so the node records altered signalling without a direction.
semaphorin-plexin signaling pathway GO:0071526 ↕ DYSREGULATED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves dysregulated semaphorin-plexin signaling pathway (GO:0071526). GO:0071526 is a biological process from the Gene Ontology.
semaphorin receptor binding GO:0030215 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this molecular function This pathophysiological event involves abnormal semaphorin receptor binding (GO:0030215). GO:0030215 is a molecular function from the Gene Ontology.
Downstream
Impaired Dendritic Spine Formation and Maturation
Defective Axon Guidance
Show evidence (2 references)
PMID:34017830 SUPPORT In vitro / ex vivo
"Co-immunoprecipitation studies have demonstrated that both variants influence protein binding of SEMA6B and PlxnA2 with varying degrees."
Patient variants, including a truncating one, alter the SEMA6B-plexin-A2 interaction.
PMID:25209245 SUPPORT Model organism
"Truncated Sema6B lacking the intracellular domain was unable to rescue the loss-of-function phenotype, confirming a receptor function of Sema6B."
In chick embryos the intracellular domain is required for SEMA6B receptor function, which is the domain removed by the disease variants.
Impaired Dendritic Spine Formation and Maturation
In cultured mouse hippocampal neurons, overexpression of a recurrent exon 17 nonsense variant (p.Trp689*) reduced dendritic spine number, with loss of mature spines, and knockdown of endogenous Sema6b had the same effect. Because over-expression of the mutant and reduction of the wild type converge on the same spine phenotype, these data do not on their own separate a dominant-negative from a loss-of-function mechanism.
hippocampal glutamatergic neuron CL:0000679 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves hippocampal glutamatergic neuron, annotated with glutamatergic neuron (CL:0000679). CL:0000679 is a cell type from the Cell Ontology.
dendritic spine development GO:0060996 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased dendritic spine development (GO:0060996). GO:0060996 is a biological process from the Gene Ontology.
Downstream
Abnormal Neural Circuit Development
Show evidence (2 references)
PMID:35604360 SUPPORT In vitro / ex vivo
"The variants p.(Val183Leu) and p.(Trp689*) led to a decrease of the total spine number compared with the wild-type."
A recurrent last-exon nonsense variant reduces spine number in primary neurons.
PMID:35604360 SUPPORT In vitro / ex vivo
"Sema6b knockdown also impairs spine density and spine maturation."
Reducing wild-type Sema6b produces the same spine phenotype, so the spine defect is a readout of reduced SEMA6B function.
Defective Axon Guidance
SEMA6B guides axons both as a receptor and as a repellent cue. In chick embryos depleted of endogenous SEMA6B, a recurrent truncating variant failed to restore the normal rostral turn of post-crossing commissural axons, and mice lacking Sema6b show misrouted hippocampal mossy fibres.
commissural neuron axon guidance GO:0071679 ↓ DECREASED Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves decreased commissural neuron axon guidance (GO:0071679). GO:0071679 is a biological process from the Gene Ontology.
Animal models
Sema6b-deficient mouse Mouse partially recapitulates Complete loss of Sema6b disturbs lamina-specific axon targeting in the hippocampus.
Downstream
Abnormal Neural Circuit Development
Show evidence (2 references)
PMID:35604360 SUPPORT Model organism
"We observed that expression of these variants in commissural neurons fails to rescue the normal axon pathway."
Variant SEMA6B, including a recurrent exon 17 nonsense variant, cannot support normal commissural axon guidance in vivo.
PMID:20484647 SUPPORT Model organism
"In Sema6B-deficient mice several mossy fibers aberrantly project to the stratum radiatum and the stratum oriens."
Loss of Sema6b in mice misroutes axons in the hippocampus, showing that SEMA6B is needed for lamina-specific wiring in the mammalian brain.
Abnormal Neural Circuit Development
SEMA6B is expressed broadly in the developing and mature brain, most strongly in cortical excitatory neurons and cerebellar Purkinje cells. In zebrafish, mosaic truncation of the last coding exon of both sema6b orthologs caused small heads, a smaller optic tectum and defective neuronal development, whereas truncation near the start codon caused only a mild phenotype. The developmental timing of the human disease, with delay before seizure onset, fits a disorder of circuit formation, but which circuits are miswired in patients has not been shown.
cortical excitatory neuron CL:0000679 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cortical excitatory neuron, annotated with glutamatergic neuron (CL:0000679). CL:0000679 is a cell type from the Cell Ontology. cerebellar Purkinje cell CL:0000121 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cerebellar Purkinje cell, annotated with Purkinje cell (CL:0000121). CL:0000121 is a cell type from the Cell Ontology.
neuron development GO:0048666 ⚠ ABNORMAL Gene Ontology (GO) Relation: this pathophysiological event involves this biological process This pathophysiological event involves abnormal neuron development (GO:0048666). GO:0048666 is a biological process from the Gene Ontology.
cerebral cortex UBERON:0000956 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebral cortex (UBERON:0000956). UBERON:0000956 is an anatomical location from the Uberon multi-species anatomy ontology.
Animal models
Zebrafish sema6ba/sema6bb exon 17 F0 crispants Zebrafish partially recapitulates Last-exon truncation disturbs brain development more than start-codon disruption, mirroring the position dependence of the human variants.
Downstream
Cortical Hyperexcitability
Cerebellar Dysfunction
Global Developmental Delay
Hypotonia
Intellectual Disability
Microcephaly
Show evidence (2 references)
PMID:32169168 SUPPORT Model organism
"Zebrafish expressing truncating variants in the NMD(-) region of SEMA6B orthologs displayed defective development of brain neurons and enhanced pentylenetetrazole-induced seizure behavior."
Truncation of the zebrafish orthologs in the decay-escape region disturbs brain neuronal development.
PMID:32169168 SUPPORT Model organism
"In P12–P60 mouse brains, Sema6b was expressed in excitatory neurons in the cerebral cortex and in cerebellar Purkinje cells"
Places Sema6b expression in the cortical and cerebellar neurons whose dysfunction would account for the seizures, myoclonus and ataxia.
Cortical Hyperexcitability
Patients show the neurophysiological signs of a hyperexcitable sensorimotor cortex typical of the progressive myoclonus epilepsies: giant or enlarged somatosensory evoked potentials, an enhanced long-latency C reflex, and myoclonic jerks preceded by a cortical potential on jerk-locked back averaging. Zebrafish carrying last-exon truncations of the sema6b orthologs were more sensitive to the convulsant pentylenetetrazole. How altered SEMA6B signalling produces this hyperexcitability, for example whether inhibitory interneurons are involved, is unknown.
cerebral cortex UBERON:0000956 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebral cortex (UBERON:0000956). UBERON:0000956 is an anatomical location from the Uberon multi-species anatomy ontology.
Animal models
Zebrafish sema6ba/sema6bb exon 17 F0 crispants Zebrafish partially recapitulates Larvae with last-exon truncations show heightened seizure-like behaviour after pentylenetetrazole exposure.
Downstream
Seizures
Bilateral Tonic-Clonic Seizures
Atonic Seizures
Absence Seizures
Non-Convulsive Status Epilepticus
Myoclonus
Cortical Action Myoclonus
Giant Somatosensory Evoked Potentials
Photoparoxysmal Response
Show evidence (3 references)
PMID:32169168 SUPPORT Human clinical
"Somatosensory evoked potential (SEP) tests showed high amplitudes of P24 and N33 electrical potentials in individual 1 and giant SEP in individual 2."
Enlarged cortical evoked responses are a direct measure of sensorimotor cortical hyperexcitability.
PMID:36719163 SUPPORT Human clinical
"jerk‐locked back averaging indicated their cortical origin"
Back-averaging places the origin of the myoclonus in the cortex.
PMID:32169168 SUPPORT Model organism
"Our zebrafish sema6ba/b-ex.17-injected crispants demonstrated increased PTZ-mediated hyperactive responses compared with the response of the sema6ba/b-ex.2-injected larvae."
Truncation in the decay-escape region, but not near the start codon, raises seizure susceptibility in zebrafish larvae.
Cerebellar Dysfunction
Cerebellar signs (ataxia, intention tremor) were present in every patient of the discovery series, and mild cerebellar atrophy was seen on MRI in some; most patients nonetheless have normal brain imaging. Sema6b is expressed in cerebellar Purkinje cells, but no study has examined the cerebellum in SEMA6B disease or in a model, so this node rests on the clinical signs and the expression pattern.
cerebellar Purkinje cell CL:0000121 Cell Ontology (CL) Relation: this pathophysiological event involves this cell type This pathophysiological event involves cerebellar Purkinje cell, annotated with Purkinje cell (CL:0000121). CL:0000121 is a cell type from the Cell Ontology.
cerebellum UBERON:0002037 Uberon multi-species anatomy ontology (UBERON) Relation: this pathophysiological event occurs in this anatomical location This pathophysiological event occurs in cerebellum (UBERON:0002037). UBERON:0002037 is an anatomical location from the Uberon multi-species anatomy ontology.
Downstream
Ataxia
Intention Tremor
Cerebellar Atrophy
Show evidence (1 reference)
PMID:32169168 SUPPORT Human clinical
"cerebellar findings (ataxia, intention tremor, and/or mild cerebellar atrophy on MRI) in all four individuals"
Cerebellar involvement was a consistent clinical feature of the discovery cohort.
⬡

Pathograph

Use Group by to collapse related nodes into one box. Use the checkboxes to hide or show graph categories. Hover nodes for evidence and cross-linked metadata.
Pathograph: causal mechanism network for Progressive Myoclonic Epilepsy Type 11 Interactive directed graph showing how pathophysiology mechanisms, phenotypes, genetic factors and variants, experimental models, environmental triggers, and treatments relate through causal and linked edges.
●

Phenotypes

21
Head and Neck 1
Microcephaly HP:0000252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Microcephaly (HP:0000252). HP:0000252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32169168 SUPPORT Human clinical
"Microcephaly was recognized in individual 2, individual 3, and individual 4."
Microcephaly in three of the four discovery patients.
Musculoskeletal 2
Hypotonia VERY_FREQUENT HP:0001252 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Hypotonia (HP:0001252). HP:0001252 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:35604360 SUPPORT Human clinical
"Fourteen patients had hypotonia in infancy and early childhood and had delayed development."
Hypotonia in 14 of 16 patients ascertained for intellectual disability.
Spasticity HP:0001257 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Spasticity (HP:0001257). HP:0001257 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:32169168 SUPPORT Human clinical
"pyramidal-tract signs (spasticity, increased deep tendon reflex, and/or pathological reflex) in individual 1 and individual 2"
Pyramidal signs in two of the four discovery patients.
PMID:36719163 SUPPORT Human clinical
"At last neurological examination (25 years old), he showed severe cerebellar ataxia, marked spasticity, and dysarthria."
Marked spasticity in an adult with the progressive presentation.
Nervous System 18
Global Developmental Delay HP:0001263 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Global developmental delay (HP:0001263), qualified as infantile onset. HP:0001263 is a phenotype from the Human Phenotype Ontology.
Onset: INFANTILE
Show evidence (2 references)
PMID:32169168 SUPPORT Human clinical
"Developmental milestones were mildly delayed but apparently normal until 2 years."
Mild early delay preceded seizures and regression in the discovery cohort.
PMID:35604360 SUPPORT Human clinical
"Fourteen patients had hypotonia in infancy and early childhood and had delayed development."
Delayed development was near universal in a cohort of 16 patients.
Intellectual Disability HP:0001249 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intellectual disability (HP:0001249). HP:0001249 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:35604360 SUPPORT Human clinical
"our study indicates that the clinical spectrum is wider and also includes non-syndromic ID without epilepsy or myoclonus."
Intellectual disability occurs across the spectrum, including patients without epilepsy.
PMID:36719163 SUPPORT Human clinical
"PME phenotype followed developmental delay, was associated with a progressive moderate‐to‐severe intellectual disability and motor regression due to both myoclonus worsening and additional neurological deficits."
In the progressive myoclonic presentation the intellectual disability is moderate to severe and progressive.
Seizures VERY_FREQUENT HP:0001250 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Seizure (HP:0001250), qualified as childhood onset. HP:0001250 is a phenotype from the Human Phenotype Ontology.
Onset: CHILDHOOD
Show evidence (3 references)
PMID:36719163 SUPPORT Human clinical
"Seizures were present in 25 of 29 patients, including two with non‐convulsive status epilepticus (NCSE), with variable age of onset between 11 months to 10 years."
Seizures in 25 of 29 published patients.
PMID:32169168 SUPPORT Human clinical
"Epilepsy started from the age of 1 year 5 months until about 6 years."
Age of seizure onset in the discovery cohort.
PMID:39419291 SUPPORT REVIEW SYNTHESIS Human clinical
"Response to antiseizure medications was also highly variable, almost half of the patients had pharmacoresistant seizures."
Systematic review of 36 patients reporting pharmacoresistance in about half.
Bilateral Tonic-Clonic Seizures HP:0002069 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Generalized tonic-clonic seizure, annotated with Bilateral tonic-clonic seizure (HP:0002069). HP:0002069 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32169168 SUPPORT Human clinical
"The types of epilepsy were generalized tonic-clonic seizure (GTCS) in individual 1 and individual 2, absence seizure in individual 1 and individual 3, and atonic seizure in individual 1, individual 2, and individual 4."
Generalized tonic-clonic seizures in two of the four discovery patients.
Atonic Seizures HP:0010819 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Atonic seizure (HP:0010819). HP:0010819 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32169168 SUPPORT Human clinical
"The types of epilepsy were generalized tonic-clonic seizure (GTCS) in individual 1 and individual 2, absence seizure in individual 1 and individual 3, and atonic seizure in individual 1, individual 2, and individual 4."
Atonic seizures in three of the four discovery patients.
Absence Seizures Generalized non-motor (absence) seizure HP:0002121 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Absence seizure, annotated with Generalized non-motor (absence) seizure (HP:0002121). HP:0002121 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32169168 SUPPORT Human clinical
"The types of epilepsy were generalized tonic-clonic seizure (GTCS) in individual 1 and individual 2, absence seizure in individual 1 and individual 3, and atonic seizure in individual 1, individual 2, and individual 4."
Absence seizures in two of the four discovery patients.
Non-Convulsive Status Epilepticus OCCASIONAL Status epilepticus without prominent motor symptoms HP:0031475 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Non-convulsive status epilepticus, annotated with Status epilepticus without prominent motor symptoms (HP:0031475). HP:0031475 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:36719163 SUPPORT Human clinical
"Seizures were present in 25 of 29 patients, including two with non‐convulsive status epilepticus (NCSE), with variable age of onset between 11 months to 10 years."
Non-convulsive status epilepticus in two of 29 published patients.
PMID:35573939 SUPPORT Human clinical
"He experienced recurrent myoclonic seizures, non-convulsive status epilepticus (NCSE), atonic seizures, and atypical absence seizures during the last 2 years."
Case report of non-convulsive status epilepticus with the other seizure types of the disorder.
Myoclonus FREQUENT HP:0001336 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Myoclonus (HP:0001336). HP:0001336 is a phenotype from the Human Phenotype Ontology.
Sequelae: Motor Regression
Show evidence (1 reference)
PMID:36719163 SUPPORT Human clinical
"Sixteen patients had myoclonic jerks. Of these, only 10 had a clear‐cut PME phenotype with prominent action‐activated myoclonus."
Myoclonic jerks in 16 of 29 published patients.
Cortical Action Myoclonus FREQUENT Cortical myoclonus HP:0040148 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cortical action myoclonus, annotated with Cortical myoclonus (HP:0040148), qualified as course progressive. HP:0040148 is a phenotype from the Human Phenotype Ontology.
Course: PROGRESSIVE
Show evidence (2 references)
PMID:36719163 SUPPORT Human clinical
"Sixteen patients had myoclonic jerks. Of these, only 10 had a clear‐cut PME phenotype with prominent action‐activated myoclonus."
Prominent action myoclonus in 10 of 29 published patients.
PMID:36719163 SUPPORT Human clinical
"jerk‐locked back averaging indicated their cortical origin"
Neurophysiology confirming that the myoclonus is cortical.
Giant Somatosensory Evoked Potentials HP:0001312 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Giant somatosensory evoked potentials (HP:0001312). HP:0001312 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:32169168 SUPPORT Human clinical
"Somatosensory evoked potential (SEP) tests showed high amplitudes of P24 and N33 electrical potentials in individual 1 and giant SEP in individual 2."
Enlarged and giant evoked potentials in the discovery cohort.
PMID:36873942 SUPPORT Human clinical
"Somatosensory evoked potential (SEP) showed giant evoked potentials in the bilateral upper limbs and enhanced C reflexes after stimulation of the median nerve bilaterally."
Giant evoked potentials and an enhanced C reflex in an adult-onset case.
Photoparoxysmal Response EEG with photoparoxysmal response HP:0010852 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is EEG with photoparoxysmal response (HP:0010852). HP:0010852 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36719163 SUPPORT Human clinical
"Accordingly, epileptic abnormalities at the EEG were both diffuse and multifocal; PPR was present in two cases."
A photoparoxysmal EEG response in two of three patients in the series.
Developmental Regression HP:0002376 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Developmental regression (HP:0002376). HP:0002376 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32169168 SUPPORT Human clinical
"Regression started from 2–4 years in individual 3 and individual 4"
Regression in early childhood in the discovery cohort.
Motor Regression FREQUENT HP:0033044 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Motor regression (HP:0033044). HP:0033044 is a phenotype from the Human Phenotype Ontology.
Sequelae: Loss of Ambulation
Show evidence (1 reference)
PMID:36719163 SUPPORT Human clinical
"Sixteen patients had a progressive impairment of motor ability; 10 cases reported ataxia and spasticity."
Progressive loss of motor ability in 16 of 29 published patients.
Loss of Ambulation HP:0002505 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Loss of ambulation (HP:0002505). HP:0002505 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32169168 SUPPORT Human clinical
"The affected individuals were wheelchair bound or only walked with support at 10–14 years."
Loss of independent walking by early adolescence in the discovery cohort.
Loss of Speech FREQUENT HP:0002371 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Loss of speech (HP:0002371). HP:0002371 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:36719163 SUPPORT Human clinical
"In 10 subjects severe cognitive regression with loss of speech ability was reported."
Loss of speech in 10 of 29 published patients.
Ataxia HP:0001251 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Ataxia (HP:0001251). HP:0001251 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:32169168 SUPPORT Human clinical
"cerebellar findings (ataxia, intention tremor, and/or mild cerebellar atrophy on MRI) in all four individuals"
Cerebellar signs including ataxia in all four discovery patients.
PMID:36719163 SUPPORT Human clinical
"At last neurological examination (25 years old), he showed severe cerebellar ataxia, marked spasticity, and dysarthria."
Severe cerebellar ataxia in an adult with the progressive presentation.
Intention Tremor HP:0002080 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Intention tremor (HP:0002080). HP:0002080 is a phenotype from the Human Phenotype Ontology.
Show evidence (1 reference)
PMID:32169168 SUPPORT Human clinical
"cerebellar findings (ataxia, intention tremor, and/or mild cerebellar atrophy on MRI) in all four individuals"
Intention tremor is one of the cerebellar signs in the discovery cohort.
Cerebellar Atrophy HP:0001272 Human Phenotype Ontology (HP) Relation: this clinical feature is this phenotype This clinical feature is Cerebellar atrophy (HP:0001272). HP:0001272 is a phenotype from the Human Phenotype Ontology.
Show evidence (2 references)
PMID:32169168 SUPPORT Human clinical
"cerebellar findings (ataxia, intention tremor, and/or mild cerebellar atrophy on MRI) in all four individuals"
Mild cerebellar atrophy on MRI in the discovery cohort.
PMID:36873942 SUPPORT Human clinical
"Magnetic resonance imaging (MRI) revealed mild cortical and cerebellar atrophy"
Mild cerebellar atrophy in an adult-onset case.
🧬

Genetic Associations

1
SEMA6B (De Novo Variant)
Gene: SEMA6B hgnc:10739 HUGO Gene Nomenclature Committee (hgnc) Relation: this disease-associated gene is this gene This disease-associated gene is SEMA6B (hgnc:10739). hgnc:10739 is a gene from the HUGO Gene Nomenclature Committee. relationship_type: CAUSATIVE variant_origin: DE_NOVO
Show evidence (3 references)
PMID:32169168 SUPPORT Human clinical
"In summary, we show that truncating DNVs in the final exon of SEMA6B cause progressive myoclonic epilepsy."
Discovery study establishing last-exon truncating SEMA6B variants as the cause of the disease.
PMID:33798445 SUPPORT Human clinical
"Second, we independently validate SEMA6B as a dominant PME gene in two unrelated individuals."
Independent replication in a separate PME cohort.
CGGV:assertion_dc080017-6a01-4da0-a9f5-e89710890a4c-2025-01-21T170000.000Z SUPPORT Other
"The vast majority of reported variants are protein truncating variants found in the last exon of the gene (exon 17) that are either predicted or proven"
ClinGen's summary of the variant spectrum across reported patients.
Variants (2)
SEMA6B c.1991del (p.Gly664Alafs*21) Pathogenic
Recurrent exon 17 frameshift, found in two unrelated families in the discovery study and again in a later intellectual-disability cohort.
Show evidence (1 reference)
PMID:32169168 SUPPORT Human clinical
"We identified two frameshift DNVs, c.1950_1969dup (p.Arg657Profs∗35) and c.1991del, the latter being identical to one of the variants found through the initial analysis of the 346 trios."
Recurrence of the same de novo frameshift in unrelated families.
SEMA6B c.2066G>A (p.Trp689*) Pathogenic
Recurrent exon 17 nonsense variant, reported in a patient with zonisamide-responsive progressive myoclonic epilepsy and in the intellectual-disability cohort, and the variant used in neuronal and chick functional studies.
Show evidence (1 reference)
PMID:35604360 SUPPORT Human clinical
"Three of these variants were previously described, c.1976_1982del p.(Ala659Valfs*24) and c. 1991del p.(Gly664Alafs*21) in Hamanaka et al. (14) and c.2066G>A p.(Trp689*) in Herzog et al. (10)."
p.Trp689*, first reported by Herzog et al., recurred in this cohort, as did the two discovery-study frameshifts.
💊

Medical Actions

1
Antiseizure and Antimyoclonic Pharmacotherapy
Action: PharmacotherapyNCI Thesaurus (NCIT) Relation: this treatment is this clinical intervention This treatment is Pharmacotherapy (NCIT:C15986). NCIT:C15986 is a clinical intervention from the NCI Thesaurus. NCIT:C15986
Agent: valproic acid CHEBI:39867 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses valproic acid (CHEBI:39867). CHEBI:39867 is a therapeutic agent from Chemical Entities of Biological Interest. levetiracetam CHEBI:6437 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses levetiracetam (CHEBI:6437). CHEBI:6437 is a therapeutic agent from Chemical Entities of Biological Interest. zonisamide CHEBI:10127 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses zonisamide (CHEBI:10127). CHEBI:10127 is a therapeutic agent from Chemical Entities of Biological Interest. clobazam CHEBI:31413 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses clobazam (CHEBI:31413). CHEBI:31413 is a therapeutic agent from Chemical Entities of Biological Interest. piracetam CHEBI:32010 Chemical Entities of Biological Interest (CHEBI) Relation: this treatment uses this therapeutic agent This treatment uses piracetam (CHEBI:32010). CHEBI:32010 is a therapeutic agent from Chemical Entities of Biological Interest.
Platform: Small molecule
Treatment is symptomatic with antiseizure medications. Valproate and levetiracetam have controlled seizures in some patients; zonisamide improved positive and negative truncal myoclonus and gait in one patient; and clobazam with valproate and piracetam ended non-convulsive status epilepticus in another. About half of patients have pharmacoresistant seizures, and no disease-modifying therapy exists.
Target Phenotypes: Myoclonus HP:0001336 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Myoclonus (HP:0001336). HP:0001336 is a phenotype from the Human Phenotype Ontology. Seizure HP:0001250 Human Phenotype Ontology (HP) Relation: this treatment targets this phenotype This treatment targets Seizure (HP:0001250). HP:0001250 is a phenotype from the Human Phenotype Ontology.
Show evidence (3 references)
PMID:34092044 SUPPORT Human clinical
"In the present case, treatment with zonisamide caused clinical improvement, particularly of positive and negative truncal myoclonus, considerably improving patient's gait and thus mobility."
Single-patient report of zonisamide improving myoclonus and mobility.
PMID:35573939 SUPPORT Human clinical
"Notably, NCSE was controlled by a combination of piracetam with clobazam and valproic acid instead of intravenous infusion of midazolam and phenobarbital."
Single-patient report of a drug combination ending non-convulsive status epilepticus.
PMID:36719163 SUPPORT Human clinical
"Treatment with VPA allowed complete seizure freedom."
Valproate gave seizure freedom in one patient of the series.
🔬

Diagnosis

1
Molecular Genetic Testing
Diagnosis rests on a heterozygous pathogenic SEMA6B variant, usually a de novo truncating variant in exon 17, found by exome sequencing or a multigene epilepsy panel. Because SEMA6B truncating variants outside the decay-escape region are tolerated, the position of a truncating variant is central to its interpretation. Supportive findings are giant or enlarged somatosensory evoked potentials, an enhanced C reflex and cortical myoclonus on polygraphy; brain MRI is usually normal.
Differential diagnosis includes the other progressive myoclonus epilepsies with developmental delay and the developmental and epileptic encephalopathies, notably Lennox-Gastaut syndrome and epilepsy with myoclonic-atonic seizures, which several SEMA6B patients were first diagnosed with. One reported patient's presentation was initially taken for Angelman syndrome.
Show evidence (2 references)
PMID:32169168 SUPPORT Human clinical
"Truncating variants in the NMD(−) region of SEMA6B were not observed in general populations (i.e., the “non-neuro” subset of gnomAD), except for one at the extreme C terminus, whreas truncating variants were observed in the NMD(+) region"
The region of a truncating variant separates disease alleles from those tolerated in the population, which is what interpretation turns on.
PMID:36719163 SUPPORT Human clinical
"The remaining six cases presented myoclonic jerks in the context of polymorphic seizures, suggestive of DEE (Lennox‐Gastaut or epilepsy with myoclonic atonic seizures)."
Myoclonus in SEMA6B disease can present within a developmental and epileptic encephalopathy, which shapes the differential diagnosis.
📊

Prevalence

1
Worldwide (published case reports)
Cases/families reported in the literature
No population estimate exists. A 2025 systematic review collected 36 reported patients from 12 studies, of whom 18 had progressive myoclonus epilepsy, 13 developmental and epileptic encephalopathy, 4 a neurodevelopmental disorder without epilepsy and 1 epilepsy alone.
Show evidence (1 reference)
PMID:39419291 SUPPORT REVIEW SYNTHESIS Human clinical
"Patients were divided into four different phenotypic groups according to their clinical presentations: PME (18/36), developmental and epileptic encephalopathy (13/36), neurodevelopmental disorder (4/36), and epilepsy (1/36), respectively."
Number and phenotypic distribution of reported patients.
🐁

Animal Models

2
Zebrafish sema6ba/sema6bb exon 17 F0 crispants
The only in vivo model of the disease variant class. Embryos with last-exon truncations of the sema6b orthologs had small heads, short bodies and a smaller optic tectum, and larvae showed exaggerated responses to the convulsant pentylenetetrazole; crispants targeting the start codon had a much milder phenotype. No spontaneous seizures were reported, and the animals were mosaic first-generation crispants rather than stable heterozygous lines.
Species
Zebrafish
Genotype
Mosaic F0 CRISPR-Cas9 crispants carrying frameshifts in the last coding exon (exon 17) of sema6ba, sema6bb or both, compared with crispants targeting the start codon in exon 2
Publication
PMID:32169168
Pathograph links
Abnormal Neural Circuit Development partially recapitulates fidelity: low observes: tissue Last-exon truncation disturbs brain development more than start-codon disruption, mirroring the position dependence of the human variants.
Limitations: Mosaic F0 crispants with an unknown allele mix and dosage, in a species with two sema6b paralogs; the defects measured (head size, optic tectum area) are gross morphology rather than circuit wiring, and stable heterozygous lines were not studied.
Show evidence (2 references)
PMID:32169168 SUPPORT Model organism
"ICD truncation, therefore, produces more significant CNS anomalies than the loss-of-function in a zebrafish model."
The model's central finding on position-dependent severity.
+ 1 more reference
Cortical Hyperexcitability partially recapitulates fidelity: low observes: organism Larvae with last-exon truncations show heightened seizure-like behaviour after pentylenetetrazole exposure.
Limitations: Seizure behaviour was only provoked, not spontaneous, and zebrafish larvae have no cerebral cortex, so the readout is a whole-larva excitability measure rather than cortical hyperexcitability.
Readouts
Pentylenetetrazole-induced swimming activity and convulsive behaviour
Direction: INCREASED
Interpretation: Provoked seizure susceptibility, increased in exon 17 crispants relative to exon 2 crispants.
Show evidence (1 reference)
PMID:32169168 SUPPORT Model organism
"Our zebrafish sema6ba/b-ex.17-injected crispants demonstrated increased PTZ-mediated hyperactive responses compared with the response of the sema6ba/b-ex.2-injected larvae."
The measured provoked-seizure readout.
Show evidence (1 reference)
PMID:32169168 SUPPORT Model organism
"Seizure behavior was not observed in any larvae that were not treated with PTZ"
Without the convulsant no seizure behaviour was seen, so the model shows increased susceptibility rather than spontaneous epilepsy.
Sema6b-deficient mouse
A null allele, not the human variant class. It shows that loss of Sema6b misroutes hippocampal mossy fibres, which supports a role for SEMA6B in mammalian brain wiring; no seizure or behavioural phenotype relevant to EPM11 is reported in the cited study.
Species
Mouse
Genotype
Sema6b knockout
Publication
PMID:20484647
Pathograph links
Defective Axon Guidance partially recapitulates fidelity: low Complete loss of Sema6b disturbs lamina-specific axon targeting in the hippocampus.
Limitations: A homozygous null rather than a heterozygous last-exon truncation, so it tests loss of SEMA6B rather than the truncated protein made in patients.
Show evidence (1 reference)
PMID:20484647 SUPPORT Model organism
"In Sema6B-deficient mice several mossy fibers aberrantly project to the stratum radiatum and the stratum oriens."
Axon misrouting in the Sema6b-null hippocampus.
{ }

Source YAML

click to show 
name: Progressive Myoclonic Epilepsy Type 11
creation_date: "2026-10-20T19:17:31Z"
category: Mendelian
description: >-
  Progressive myoclonic epilepsy type 11 (EPM11) is an autosomal dominant
  neurodevelopmental and epileptic disorder caused by heterozygous, almost
  always de novo, truncating variants in the last exon (exon 17) of SEMA6B,
  which encodes the class 6 transmembrane semaphorin 6B. Because these variants
  lie in the region where a premature stop codon escapes nonsense-mediated mRNA
  decay, the mutant transcript is stable and is predicted to yield a truncated
  protein that keeps its extracellular sema domain and transmembrane segment
  but lacks the intracellular domain through which class 6 semaphorins signal
  as receptors. Heterozygous truncating variants earlier in the gene occur in
  the general population, so simple haploinsufficiency is not the accepted
  mechanism; whether the truncated protein acts as a dominant negative, gains a
  toxic function, or adds to a partial loss of SEMA6B signalling is unresolved.
  Development is mildly delayed from infancy and seizures usually begin between
  about 1 and 6 years. In the classic presentation, action and cortical
  myoclonus, generalized tonic-clonic, atonic and absence seizures, cerebellar
  ataxia, pyramidal signs and cognitive and motor regression follow, with loss
  of independent walking and speech in the second decade. The same class of
  variants also produces developmental and epileptic encephalopathy without a
  recognized progressive myoclonic course and, less often, intellectual
  disability without epilepsy. This entry treats these presentations as one
  SEMA6B-related disease spectrum rather than as separate disorders, because
  they share the genotype and no genotype-phenotype correlation separates them.
synonyms:
- EPM11
- epilepsy, progressive myoclonic, 11
- PME type 11
- SEMA6B-related progressive myoclonic epilepsy
- SEMA6B-related disorder
disease_term:
  preferred_term: epilepsy, progressive myoclonic, 11
  term:
    id: MONDO:0030034
    label: epilepsy, progressive myoclonic, 11
parents:
- Progressive Myoclonus Epilepsy
classifications:
  harrisons_chapter:
  - classification_value: NEUROLOGIC
inheritance:
- name: Autosomal Dominant (predominantly de novo)
  inheritance_term:
    preferred_term: Autosomal dominant inheritance
    term:
      id: HP:0000006
      label: Autosomal dominant inheritance
  description: >-
    A single heterozygous SEMA6B variant is sufficient to cause disease. Nearly
    all reported variants arose de novo, so recurrence within a family is
    unusual. Two exceptions are reported: a family with an adult-onset course
    and a missense variant shared by two affected siblings, and a family in
    which a splice-site variant outside the last exon segregated with epilepsy
    with marked incomplete penetrance. Penetrance of the classic exon 17
    truncations cannot be judged because they are almost never inherited.
  evidence:
  - reference: PMID:42696975
    reference_title: "A novel SEMA6B splice-site variant (c.1680-2A>G) causes incompletely penetrant epilepsy via diverse aberrant transcripts."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "segregating with autosomal dominant EPM1in a family exhibiting marked incomplete penetrance"
    explanation: >-
      Dominant segregation with incomplete penetrance for a non-last-exon
      splice variant. The source abstract's "EPM1" is a typographical slip for
      EPM11, as its background sentence names EPM11 and SEMA6B.
  - reference: CGGV:assertion_dc080017-6a01-4da0-a9f5-e89710890a4c-2025-01-21T170000.000Z
    reference_title: "SEMA6B / progressive myoclonus epilepsy (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "SEMA6B | HGNC:10739 | progressive myoclonus epilepsy | MONDO:0020074 | AD | Definitive"
    explanation: >-
      ClinGen's Epilepsy Gene Curation Expert Panel classifies SEMA6B in
      autosomal dominant progressive myoclonus epilepsy as Definitive. The record
      is filed against the parent class MONDO:0020074 rather than this MONDO
      term, so it is cited for the mode of inheritance and is not recorded as a
      gene-disease validity assertion for EPM11.
  - reference: PMID:33798445
    reference_title: "Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Second, we independently validate SEMA6B as a dominant PME gene in two unrelated individuals."
    explanation: >-
      Independent replication, in an exome study of unsolved progressive
      myoclonus epilepsy, that SEMA6B acts as a dominant disease gene.
  - reference: PMID:35604360
    reference_title: "SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "SEMA6B variants were de novo in 13 out of 16 patients for whom parental DNA was available."
    explanation: >-
      Most heterozygous SEMA6B variants arise de novo, which is how this
      dominant disorder usually appears in a family.
  - reference: PMID:36873942
    reference_title: "A novel SEMA6B variant causes adult-onset progressive myoclonic epilepsy-11 in a Chinese family: A case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The proband’s sister carried the same heterozygous mutation"
    explanation: >-
      The one reported familial occurrence: two affected siblings sharing a
      heterozygous missense variant, consistent with dominant transmission.
pathophysiology:
- name: SEMA6B Last-Exon Truncating Variant Escaping NMD
  biological_scale: MOLECULAR
  description: >-
    Disease-causing variants are heterozygous nonsense and frameshift variants
    clustered in exon 17, the last exon of SEMA6B, where a premature stop codon
    does not trigger nonsense-mediated mRNA decay. In lymphoblastoid cells from
    an affected individual the mutant transcript was present at a level
    comparable to the wild-type transcript. Truncating variants upstream of
    this region, which would be degraded, are seen in the general population,
    and SEMA6B is tolerant of loss-of-function variation; the pathogenic
    variant class is therefore defined by its position, not by truncation as
    such.
  genetic_context:
    gene:
      preferred_term: SEMA6B
      term:
        id: hgnc:10739
        label: SEMA6B
    variant_origin: DE_NOVO
    zygosity: HETEROZYGOUS
    functional_impact_category: UNKNOWN
    description: >-
      Frameshift and nonsense variants in the nonsense-mediated decay escape
      region (exon 17). functional_impact_category is left UNKNOWN because
      dominant-negative, gain-of-function and loss-of-function readings of the
      truncated protein have each been proposed and none has been shown in a
      mammalian system; see the discussion sema6b_truncation_mechanism.
  downstream:
  - target: Stable Truncated SEMA6B Lacking the Intracellular Domain
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "RNA analysis of lymphoblastoid cells established from an affected individual showed that the mutant allele escaped NMD, indicating stable production of the truncated protein."
    explanation: >-
      Patient-derived cells show the mutant transcript escapes nonsense-mediated
      decay.
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Importantly, heterozygous truncating variants in the NMD(+) region of SEMA6B are observed in general populations, and SEMA6B is most likely loss-of-function tolerant."
    explanation: >-
      Truncating variants that would be degraded are tolerated in the
      population, which argues against haploinsufficiency as the mechanism.
  - reference: PMID:38091987
    reference_title: "Systematic analysis of variants escaping nonsense-mediated decay uncovers candidate Mendelian diseases."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The PTVesc-enriched genes included those with PTVescs previously described to cause dominant Mendelian disease (e.g., SEMA6B, PPM1D, and DAGLA)."
    explanation: >-
      In 29,031 neurodevelopmental-disorder trios, de novo truncating variants
      in the decay-escape region of SEMA6B were significantly enriched,
      replicating the variant class independently of the discovery cohort.
- name: Stable Truncated SEMA6B Lacking the Intracellular Domain
  biological_scale: MOLECULAR
  description: >-
    The exon 17 variants remove the intracellular domain while leaving the
    extracellular sema domain, plexin-semaphorin-integrin domain and
    transmembrane segment encoded. When one truncating variant was expressed
    in cultured cells, the truncated protein accumulated to higher levels than
    wild-type SEMA6B and failed to reach the plasma membrane, and a truncating
    variant tested in a second study was likewise mislocalized.
  downstream:
  - target: Disrupted SEMA6B-Plexin Signalling
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "All four variants occurred in the last exon of SEMA6B and lead to truncation of the intracellular domain (ICD), the region closer to the C terminus than the transmembrane domain"
    explanation: >-
      Locates the pathogenic truncations to the intracellular domain.
  - reference: PMID:34017830
    reference_title: "Novel Truncating and Missense Variants in SEMA6B in Patients With Early-Onset Epilepsy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "results in a truncated protein with remarkably increased expression compared to that of the wild type."
    explanation: >-
      In transfected cells the truncated protein is produced and is more
      abundant than the wild-type protein.
  - reference: PMID:34017830
    reference_title: "Novel Truncating and Missense Variants in SEMA6B in Patients With Early-Onset Epilepsy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The truncated protein presented more homogeneous and failed to locate in the plasma membrane."
    explanation: >-
      The truncated protein does not reach the cell surface, where SEMA6B
      normally acts.
  - reference: PMID:35604360
    reference_title: "SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The overexpression of some variants leads to a subcellular mislocalization of SEMA6B protein in HEK293T cells"
    explanation: >-
      An independent group also found mislocalization of variant SEMA6B protein.
- name: Disrupted SEMA6B-Plexin Signalling
  biological_scale: MOLECULAR
  description: >-
    SEMA6B binds plexin-A2 and acts as a receptor whose intracellular domain
    carries reverse signalling into the cell; in chick commissural neurons a
    SEMA6B lacking that domain cannot substitute for the full-length protein.
    Disease variants alter SEMA6B binding to plexin-A2 in co-immunoprecipitation
    experiments. Whether the truncated protein blocks signalling by the
    wild-type protein, signals aberrantly, or simply fails to signal is not
    established, so the node records altered signalling without a direction.
  molecular_functions:
  - preferred_term: semaphorin receptor binding
    modifier: ABNORMAL
    term:
      id: GO:0030215
      label: semaphorin receptor binding
  biological_processes:
  - preferred_term: semaphorin-plexin signaling pathway
    modifier: DYSREGULATED
    term:
      id: GO:0071526
      label: semaphorin-plexin signaling pathway
  downstream:
  - target: Impaired Dendritic Spine Formation and Maturation
    causal_link_type: DIRECT
  - target: Defective Axon Guidance
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:34017830
    reference_title: "Novel Truncating and Missense Variants in SEMA6B in Patients With Early-Onset Epilepsy."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Co-immunoprecipitation studies have demonstrated that both variants influence protein binding of SEMA6B and PlxnA2 with varying degrees."
    explanation: >-
      Patient variants, including a truncating one, alter the SEMA6B-plexin-A2
      interaction.
  - reference: PMID:25209245
    reference_title: "Semaphorin 6B acts as a receptor in post-crossing commissural axon guidance."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Truncated Sema6B lacking the intracellular domain was unable to rescue the loss-of-function phenotype, confirming a receptor function of Sema6B."
    explanation: >-
      In chick embryos the intracellular domain is required for SEMA6B receptor
      function, which is the domain removed by the disease variants.
- name: Impaired Dendritic Spine Formation and Maturation
  biological_scale: CELLULAR
  description: >-
    In cultured mouse hippocampal neurons, overexpression of a recurrent
    exon 17 nonsense variant (p.Trp689*) reduced dendritic spine number, with
    loss of mature spines, and knockdown of endogenous Sema6b had the same
    effect. Because over-expression of the mutant and reduction of the wild
    type converge on the same spine phenotype, these data do not on their own
    separate a dominant-negative from a loss-of-function mechanism.
  cell_types:
  - preferred_term: hippocampal glutamatergic neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  biological_processes:
  - preferred_term: dendritic spine development
    modifier: DECREASED
    term:
      id: GO:0060996
      label: dendritic spine development
  downstream:
  - target: Abnormal Neural Circuit Development
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:35604360
    reference_title: "SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "The variants p.(Val183Leu) and p.(Trp689*) led to a decrease of the total spine number compared with the wild-type."
    explanation: >-
      A recurrent last-exon nonsense variant reduces spine number in primary
      neurons.
  - reference: PMID:35604360
    reference_title: "SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "Sema6b knockdown also impairs spine density and spine maturation."
    explanation: >-
      Reducing wild-type Sema6b produces the same spine phenotype, so the spine
      defect is a readout of reduced SEMA6B function.
- name: Defective Axon Guidance
  biological_scale: CELLULAR
  description: >-
    SEMA6B guides axons both as a receptor and as a repellent cue. In chick
    embryos depleted of endogenous SEMA6B, a recurrent truncating variant failed
    to restore the normal rostral turn of post-crossing commissural axons, and
    mice lacking Sema6b show misrouted hippocampal mossy fibres.
  biological_processes:
  - preferred_term: commissural neuron axon guidance
    modifier: DECREASED
    term:
      id: GO:0071679
      label: commissural neuron axon guidance
  downstream:
  - target: Abnormal Neural Circuit Development
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:35604360
    reference_title: "SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "We observed that expression of these variants in commissural neurons fails to rescue the normal axon pathway."
    explanation: >-
      Variant SEMA6B, including a recurrent exon 17 nonsense variant, cannot
      support normal commissural axon guidance in vivo.
  - reference: PMID:20484647
    reference_title: "Roles of semaphorin-6B and plexin-A2 in lamina-restricted projection of hippocampal mossy fibers."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In Sema6B-deficient mice several mossy fibers aberrantly project to the stratum radiatum and the stratum oriens."
    explanation: >-
      Loss of Sema6b in mice misroutes axons in the hippocampus, showing that
      SEMA6B is needed for lamina-specific wiring in the mammalian brain.
- name: Abnormal Neural Circuit Development
  biological_scale: TISSUE
  description: >-
    SEMA6B is expressed broadly in the developing and mature brain, most
    strongly in cortical excitatory neurons and cerebellar Purkinje cells. In
    zebrafish, mosaic truncation of the last coding exon of both sema6b
    orthologs caused small heads, a smaller optic tectum and defective neuronal
    development, whereas truncation near the start codon caused only a mild
    phenotype. The developmental timing of the human disease, with delay before
    seizure onset, fits a disorder of circuit formation, but which circuits are
    miswired in patients has not been shown.
  cell_types:
  - preferred_term: cortical excitatory neuron
    term:
      id: CL:0000679
      label: glutamatergic neuron
  - preferred_term: cerebellar Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  biological_processes:
  - preferred_term: neuron development
    modifier: ABNORMAL
    term:
      id: GO:0048666
      label: neuron development
  downstream:
  - target: Cortical Hyperexcitability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Cerebellar Dysfunction
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Global Developmental Delay
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Hypotonia
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Intellectual Disability
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  - target: Microcephaly
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Zebrafish expressing truncating variants in the NMD(-) region of SEMA6B orthologs displayed defective development of brain neurons and enhanced pentylenetetrazole-induced seizure behavior."
    explanation: >-
      Truncation of the zebrafish orthologs in the decay-escape region disturbs
      brain neuronal development.
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "In P12–P60 mouse brains, Sema6b was expressed in excitatory neurons in the cerebral cortex and in cerebellar Purkinje cells"
    explanation: >-
      Places Sema6b expression in the cortical and cerebellar neurons whose
      dysfunction would account for the seizures, myoclonus and ataxia.
- name: Cortical Hyperexcitability
  biological_scale: TISSUE
  conforms_to: "epilepsy_excitation_inhibition_imbalance#Neuronal Hyperexcitability and Hypersynchrony"
  description: >-
    Patients show the neurophysiological signs of a hyperexcitable sensorimotor
    cortex typical of the progressive myoclonus epilepsies: giant or enlarged
    somatosensory evoked potentials, an enhanced long-latency C reflex, and
    myoclonic jerks preceded by a cortical potential on jerk-locked back
    averaging. Zebrafish carrying last-exon truncations of the sema6b orthologs
    were more sensitive to the convulsant pentylenetetrazole. How altered
    SEMA6B signalling produces this hyperexcitability, for example whether
    inhibitory interneurons are involved, is unknown.
  locations:
  - preferred_term: cerebral cortex
    term:
      id: UBERON:0000956
      label: cerebral cortex
  downstream:
  - target: Seizures
    causal_link_type: DIRECT
  - target: Bilateral Tonic-Clonic Seizures
    causal_link_type: DIRECT
  - target: Atonic Seizures
    causal_link_type: DIRECT
  - target: Absence Seizures
    causal_link_type: DIRECT
  - target: Non-Convulsive Status Epilepticus
    causal_link_type: DIRECT
  - target: Myoclonus
    causal_link_type: DIRECT
  - target: Cortical Action Myoclonus
    causal_link_type: DIRECT
  - target: Giant Somatosensory Evoked Potentials
    causal_link_type: DIRECT
  - target: Photoparoxysmal Response
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Somatosensory evoked potential (SEP) tests showed high amplitudes of P24 and N33 electrical potentials in individual 1 and giant SEP in individual 2."
    explanation: >-
      Enlarged cortical evoked responses are a direct measure of sensorimotor
      cortical hyperexcitability.
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "jerk‐locked back averaging indicated their cortical origin"
    explanation: >-
      Back-averaging places the origin of the myoclonus in the cortex.
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: MODEL_ORGANISM
    snippet: "Our zebrafish sema6ba/b-ex.17-injected crispants demonstrated increased PTZ-mediated hyperactive responses compared with the response of the sema6ba/b-ex.2-injected larvae."
    explanation: >-
      Truncation in the decay-escape region, but not near the start codon,
      raises seizure susceptibility in zebrafish larvae.
- name: Cerebellar Dysfunction
  biological_scale: TISSUE
  description: >-
    Cerebellar signs (ataxia, intention tremor) were present in every patient
    of the discovery series, and mild cerebellar atrophy was seen on MRI in
    some; most patients nonetheless have normal brain imaging. Sema6b is
    expressed in cerebellar Purkinje cells, but no study has examined the
    cerebellum in SEMA6B disease or in a model, so this node rests on the
    clinical signs and the expression pattern.
  cell_types:
  - preferred_term: cerebellar Purkinje cell
    term:
      id: CL:0000121
      label: Purkinje cell
  locations:
  - preferred_term: cerebellum
    term:
      id: UBERON:0002037
      label: cerebellum
  downstream:
  - target: Ataxia
    causal_link_type: DIRECT
  - target: Intention Tremor
    causal_link_type: DIRECT
  - target: Cerebellar Atrophy
    causal_link_type: INDIRECT_UNKNOWN_INTERMEDIATES
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar findings (ataxia, intention tremor, and/or mild cerebellar atrophy on MRI) in all four individuals"
    explanation: >-
      Cerebellar involvement was a consistent clinical feature of the
      discovery cohort.
phenotypes:
- name: Global Developmental Delay
  category: Neurological
  description: >-
    Mild developmental delay is usually evident before seizure onset, and
    hypotonia with delayed development is common in infancy.
  phenotype_term:
    preferred_term: Global developmental delay
    term:
      id: HP:0001263
      label: Global developmental delay
    onset:
      onset_category: INFANTILE
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Developmental milestones were mildly delayed but apparently normal until 2 years."
    explanation: >-
      Mild early delay preceded seizures and regression in the discovery
      cohort.
  - reference: PMID:35604360
    reference_title: "SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fourteen patients had hypotonia in infancy and early childhood and had delayed development."
    explanation: >-
      Delayed development was near universal in a cohort of 16 patients.
- name: Hypotonia
  category: Neurological
  description: Hypotonia in infancy and early childhood.
  phenotype_term:
    preferred_term: Hypotonia
    term:
      id: HP:0001252
      label: Hypotonia
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:35604360
    reference_title: "SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Fourteen patients had hypotonia in infancy and early childhood and had delayed development."
    explanation: >-
      Hypotonia in 14 of 16 patients ascertained for intellectual disability.
- name: Intellectual Disability
  category: Neurological
  description: >-
    Moderate to severe intellectual disability is usual and worsens with
    regression in the progressive myoclonic presentation; some patients have
    intellectual disability without epilepsy or myoclonus.
  phenotype_term:
    preferred_term: Intellectual disability
    term:
      id: HP:0001249
      label: Intellectual disability
  evidence:
  - reference: PMID:35604360
    reference_title: "SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "our study indicates that the clinical spectrum is wider and also includes non-syndromic ID without epilepsy or myoclonus."
    explanation: >-
      Intellectual disability occurs across the spectrum, including patients
      without epilepsy.
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "PME phenotype followed developmental delay, was associated with a progressive moderate‐to‐severe intellectual disability and motor regression due to both myoclonus worsening and additional neurological deficits."
    explanation: >-
      In the progressive myoclonic presentation the intellectual disability is
      moderate to severe and progressive.
- name: Seizures
  category: Neurological
  description: >-
    Epilepsy with onset usually between about 1 and 6 years (reported range
    11 months to 10 years, with rare adult onset), often polymorphic and
    pharmacoresistant in about half of patients.
  phenotype_term:
    preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
    onset:
      onset_category: CHILDHOOD
  frequency: VERY_FREQUENT
  evidence:
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seizures were present in 25 of 29 patients, including two with non‐convulsive status epilepticus (NCSE), with variable age of onset between 11 months to 10 years."
    explanation: >-
      Seizures in 25 of 29 published patients.
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Epilepsy started from the age of 1 year 5 months until about 6 years."
    explanation: >-
      Age of seizure onset in the discovery cohort.
  - reference: PMID:39419291
    reference_title: "Progressive Myoclonus Epilepsy and Beyond: A Systematic Review of SEMA6B-related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Response to antiseizure medications was also highly variable, almost half of the patients had pharmacoresistant seizures."
    explanation: >-
      Systematic review of 36 patients reporting pharmacoresistance in about
      half.
- name: Bilateral Tonic-Clonic Seizures
  category: Neurological
  phenotype_term:
    preferred_term: Generalized tonic-clonic seizure
    term:
      id: HP:0002069
      label: Bilateral tonic-clonic seizure
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The types of epilepsy were generalized tonic-clonic seizure (GTCS) in individual 1 and individual 2, absence seizure in individual 1 and individual 3, and atonic seizure in individual 1, individual 2, and individual 4."
    explanation: >-
      Generalized tonic-clonic seizures in two of the four discovery patients.
- name: Atonic Seizures
  category: Neurological
  description: Atonic seizures with head nodding or falls, often recurrent.
  phenotype_term:
    preferred_term: Atonic seizure
    term:
      id: HP:0010819
      label: Atonic seizure
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The types of epilepsy were generalized tonic-clonic seizure (GTCS) in individual 1 and individual 2, absence seizure in individual 1 and individual 3, and atonic seizure in individual 1, individual 2, and individual 4."
    explanation: >-
      Atonic seizures in three of the four discovery patients.
- name: Absence Seizures
  category: Neurological
  description: Typical and atypical absence seizures.
  phenotype_term:
    preferred_term: Absence seizure
    term:
      id: HP:0002121
      label: Generalized non-motor (absence) seizure
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The types of epilepsy were generalized tonic-clonic seizure (GTCS) in individual 1 and individual 2, absence seizure in individual 1 and individual 3, and atonic seizure in individual 1, individual 2, and individual 4."
    explanation: >-
      Absence seizures in two of the four discovery patients.
- name: Non-Convulsive Status Epilepticus
  category: Neurological
  phenotype_term:
    preferred_term: Non-convulsive status epilepticus
    term:
      id: HP:0031475
      label: Status epilepticus without prominent motor symptoms
  frequency: OCCASIONAL
  evidence:
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Seizures were present in 25 of 29 patients, including two with non‐convulsive status epilepticus (NCSE), with variable age of onset between 11 months to 10 years."
    explanation: >-
      Non-convulsive status epilepticus in two of 29 published patients.
  - reference: PMID:35573939
    reference_title: "Non-convulsive Status Epilepticus in SEMA6B-Related Progressive Myoclonic Epilepsy: A Case Report With Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "He experienced recurrent myoclonic seizures, non-convulsive status epilepticus (NCSE), atonic seizures, and atypical absence seizures during the last 2 years."
    explanation: >-
      Case report of non-convulsive status epilepticus with the other seizure
      types of the disorder.
- name: Myoclonus
  category: Neurological
  description: >-
    Myoclonic jerks, positive and negative, occur in about half of reported
    patients; in some they form part of a progressive myoclonic epilepsy and in
    others part of a polymorphic developmental and epileptic encephalopathy.
  phenotype_term:
    preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  frequency: FREQUENT
  sequelae:
  - target: Motor Regression
    causal_link_type: DIRECT
    description: >-
      Worsening myoclonus is one of the two causes of motor regression named
      in the published appraisal, and treating truncal myoclonus restored gait
      in one patient.
    evidence:
    - reference: PMID:34092044
      reference_title: "Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "In the present case, treatment with zonisamide caused clinical improvement, particularly of positive and negative truncal myoclonus, considerably improving patient's gait and thus mobility."
      explanation: >-
        Improvement in myoclonus improved gait, showing that the myoclonus
        itself contributes to the loss of mobility.
  evidence:
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sixteen patients had myoclonic jerks. Of these, only 10 had a clear‐cut PME phenotype with prominent action‐activated myoclonus."
    explanation: >-
      Myoclonic jerks in 16 of 29 published patients.
- name: Cortical Action Myoclonus
  category: Neurological
  description: >-
    Progressive, disabling action-activated myoclonus of cortical origin, the
    defining feature of the progressive myoclonic presentation, usually
    emerging or worsening in the second decade.
  phenotype_term:
    preferred_term: Cortical action myoclonus
    term:
      id: HP:0040148
      label: Cortical myoclonus
    clinical_course: PROGRESSIVE
  frequency: FREQUENT
  evidence:
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sixteen patients had myoclonic jerks. Of these, only 10 had a clear‐cut PME phenotype with prominent action‐activated myoclonus."
    explanation: >-
      Prominent action myoclonus in 10 of 29 published patients.
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "jerk‐locked back averaging indicated their cortical origin"
    explanation: >-
      Neurophysiology confirming that the myoclonus is cortical.
- name: Giant Somatosensory Evoked Potentials
  category: Neurological
  phenotype_term:
    preferred_term: Giant somatosensory evoked potentials
    term:
      id: HP:0001312
      label: Giant somatosensory evoked potentials
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Somatosensory evoked potential (SEP) tests showed high amplitudes of P24 and N33 electrical potentials in individual 1 and giant SEP in individual 2."
    explanation: >-
      Enlarged and giant evoked potentials in the discovery cohort.
  - reference: PMID:36873942
    reference_title: "A novel SEMA6B variant causes adult-onset progressive myoclonic epilepsy-11 in a Chinese family: A case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Somatosensory evoked potential (SEP) showed giant evoked potentials in the bilateral upper limbs and enhanced C reflexes after stimulation of the median nerve bilaterally."
    explanation: >-
      Giant evoked potentials and an enhanced C reflex in an adult-onset case.
- name: Photoparoxysmal Response
  category: Neurological
  phenotype_term:
    preferred_term: EEG with photoparoxysmal response
    term:
      id: HP:0010852
      label: EEG with photoparoxysmal response
  evidence:
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Accordingly, epileptic abnormalities at the EEG were both diffuse and multifocal; PPR was present in two cases."
    explanation: >-
      A photoparoxysmal EEG response in two of three patients in the series.
- name: Developmental Regression
  category: Neurological
  description: >-
    Cognitive and motor regression beginning in early childhood or during the
    second decade, in the progressive myoclonic presentation.
  phenotype_term:
    preferred_term: Developmental regression
    term:
      id: HP:0002376
      label: Developmental regression
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Regression started from 2–4 years in individual 3 and individual 4"
    explanation: >-
      Regression in early childhood in the discovery cohort.
- name: Motor Regression
  category: Neurological
  phenotype_term:
    preferred_term: Motor regression
    term:
      id: HP:0033044
      label: Motor regression
  frequency: FREQUENT
  sequelae:
  - target: Loss of Ambulation
    causal_link_type: DIRECT
  evidence:
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Sixteen patients had a progressive impairment of motor ability; 10 cases reported ataxia and spasticity."
    explanation: >-
      Progressive loss of motor ability in 16 of 29 published patients.
- name: Loss of Ambulation
  category: Neurological
  phenotype_term:
    preferred_term: Loss of ambulation
    term:
      id: HP:0002505
      label: Loss of ambulation
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The affected individuals were wheelchair bound or only walked with support at 10–14 years."
    explanation: >-
      Loss of independent walking by early adolescence in the discovery
      cohort.
- name: Loss of Speech
  category: Neurological
  description: Severe cognitive regression with loss of speech ability.
  phenotype_term:
    preferred_term: Loss of speech
    term:
      id: HP:0002371
      label: Loss of speech
  frequency: FREQUENT
  evidence:
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In 10 subjects severe cognitive regression with loss of speech ability was reported."
    explanation: >-
      Loss of speech in 10 of 29 published patients.
- name: Ataxia
  category: Neurological
  phenotype_term:
    preferred_term: Ataxia
    term:
      id: HP:0001251
      label: Ataxia
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar findings (ataxia, intention tremor, and/or mild cerebellar atrophy on MRI) in all four individuals"
    explanation: >-
      Cerebellar signs including ataxia in all four discovery patients.
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At last neurological examination (25 years old), he showed severe cerebellar ataxia, marked spasticity, and dysarthria."
    explanation: >-
      Severe cerebellar ataxia in an adult with the progressive presentation.
- name: Intention Tremor
  category: Neurological
  phenotype_term:
    preferred_term: Intention tremor
    term:
      id: HP:0002080
      label: Intention tremor
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar findings (ataxia, intention tremor, and/or mild cerebellar atrophy on MRI) in all four individuals"
    explanation: >-
      Intention tremor is one of the cerebellar signs in the discovery cohort.
- name: Cerebellar Atrophy
  category: Neurological
  description: >-
    Mild cerebellar atrophy in a minority of patients; brain MRI is normal in
    most.
  phenotype_term:
    preferred_term: Cerebellar atrophy
    term:
      id: HP:0001272
      label: Cerebellar atrophy
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "cerebellar findings (ataxia, intention tremor, and/or mild cerebellar atrophy on MRI) in all four individuals"
    explanation: >-
      Mild cerebellar atrophy on MRI in the discovery cohort.
  - reference: PMID:36873942
    reference_title: "A novel SEMA6B variant causes adult-onset progressive myoclonic epilepsy-11 in a Chinese family: A case report and literature review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Magnetic resonance imaging (MRI) revealed mild cortical and cerebellar atrophy"
    explanation: >-
      Mild cerebellar atrophy in an adult-onset case.
- name: Spasticity
  category: Neurological
  description: Pyramidal tract signs including spasticity and hyperreflexia.
  phenotype_term:
    preferred_term: Spasticity
    term:
      id: HP:0001257
      label: Spasticity
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "pyramidal-tract signs (spasticity, increased deep tendon reflex, and/or pathological reflex) in individual 1 and individual 2"
    explanation: >-
      Pyramidal signs in two of the four discovery patients.
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "At last neurological examination (25 years old), he showed severe cerebellar ataxia, marked spasticity, and dysarthria."
    explanation: >-
      Marked spasticity in an adult with the progressive presentation.
- name: Microcephaly
  category: Neurological
  phenotype_term:
    preferred_term: Microcephaly
    term:
      id: HP:0000252
      label: Microcephaly
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Microcephaly was recognized in individual 2, individual 3, and individual 4."
    explanation: >-
      Microcephaly in three of the four discovery patients.
genetic:
- name: SEMA6B
  gene_term:
    preferred_term: SEMA6B
    term:
      id: hgnc:10739
      label: SEMA6B
  association: De Novo Variant
  presence: Positive
  variant_origin: DE_NOVO
  relationship_type: CAUSATIVE
  notes: >-
    Nearly all pathogenic variants are frameshift or nonsense variants in exon
    17 (NM_032108), the last exon, where they escape nonsense-mediated decay.
    Missense variants, a splice-site variant and one upstream nonsense variant
    have also been reported, the last in a mildly affected patient with
    unavailable paternal DNA whose variant was also seen in unaffected adults;
    the pathogenicity of these non-truncating and upstream classes is less
    secure. ClinGen classifies SEMA6B in autosomal dominant progressive
    myoclonus epilepsy (MONDO:0020074) as Definitive; that record is filed
    against the parent class, so it is not copied into gene_disease_validity
    for this entry.
  variants:
  - name: SEMA6B c.1991del (p.Gly664Alafs*21)
    description: >-
      Recurrent exon 17 frameshift, found in two unrelated families in the
      discovery study and again in a later intellectual-disability cohort.
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:32169168
      reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "We identified two frameshift DNVs, c.1950_1969dup (p.Arg657Profs∗35) and c.1991del, the latter being identical to one of the variants found through the initial analysis of the 346 trios."
      explanation: >-
        Recurrence of the same de novo frameshift in unrelated families.
  - name: SEMA6B c.2066G>A (p.Trp689*)
    description: >-
      Recurrent exon 17 nonsense variant, reported in a patient with
      zonisamide-responsive progressive myoclonic epilepsy and in the
      intellectual-disability cohort, and the variant used in neuronal and
      chick functional studies.
    clinical_significance: PATHOGENIC
    evidence:
    - reference: PMID:35604360
      reference_title: "SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance."
      supports: SUPPORT
      evidence_source: HUMAN_CLINICAL
      snippet: "Three of these variants were previously described, c.1976_1982del p.(Ala659Valfs*24) and c. 1991del p.(Gly664Alafs*21) in Hamanaka et al. (14) and c.2066G>A p.(Trp689*) in Herzog et al. (10)."
      explanation: >-
        p.Trp689*, first reported by Herzog et al., recurred in this cohort,
        as did the two discovery-study frameshifts.
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In summary, we show that truncating DNVs in the final exon of SEMA6B cause progressive myoclonic epilepsy."
    explanation: >-
      Discovery study establishing last-exon truncating SEMA6B variants as the
      cause of the disease.
  - reference: PMID:33798445
    reference_title: "Progressive myoclonus epilepsies-Residual unsolved cases have marked genetic heterogeneity including dolichol-dependent protein glycosylation pathway genes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Second, we independently validate SEMA6B as a dominant PME gene in two unrelated individuals."
    explanation: >-
      Independent replication in a separate PME cohort.
  - reference: CGGV:assertion_dc080017-6a01-4da0-a9f5-e89710890a4c-2025-01-21T170000.000Z
    reference_title: "SEMA6B / progressive myoclonus epilepsy (Definitive)"
    supports: SUPPORT
    evidence_source: OTHER
    snippet: "The vast majority of reported variants are protein truncating variants found in the last exon of the gene (exon 17) that are either predicted or proven"
    explanation: >-
      ClinGen's summary of the variant spectrum across reported patients.
diagnosis:
- name: Molecular Genetic Testing
  description: >-
    Diagnosis rests on a heterozygous pathogenic SEMA6B variant, usually a de
    novo truncating variant in exon 17, found by exome sequencing or a
    multigene epilepsy panel. Because SEMA6B truncating variants outside the
    decay-escape region are tolerated, the position of a truncating variant
    is central to its interpretation. Supportive findings are giant or enlarged
    somatosensory evoked potentials, an enhanced C reflex and cortical
    myoclonus on polygraphy; brain MRI is usually normal.
  notes: >-
    Differential diagnosis includes the other progressive myoclonus epilepsies
    with developmental delay and the developmental and epileptic
    encephalopathies, notably Lennox-Gastaut syndrome and epilepsy with
    myoclonic-atonic seizures, which several SEMA6B patients were first
    diagnosed with. One reported patient's presentation was initially taken
    for Angelman syndrome.
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Truncating variants in the NMD(−) region of SEMA6B were not observed in general populations (i.e., the “non-neuro” subset of gnomAD), except for one at the extreme C terminus, whreas truncating variants were observed in the NMD(+) region"
    explanation: >-
      The region of a truncating variant separates disease alleles from those
      tolerated in the population, which is what interpretation turns on.
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "The remaining six cases presented myoclonic jerks in the context of polymorphic seizures, suggestive of DEE (Lennox‐Gastaut or epilepsy with myoclonic atonic seizures)."
    explanation: >-
      Myoclonus in SEMA6B disease can present within a developmental and
      epileptic encephalopathy, which shapes the differential diagnosis.
treatments:
- name: Antiseizure and Antimyoclonic Pharmacotherapy
  description: >-
    Treatment is symptomatic with antiseizure medications. Valproate and
    levetiracetam have controlled seizures in some patients; zonisamide
    improved positive and negative truncal myoclonus and gait in one patient;
    and clobazam with valproate and piracetam ended non-convulsive status
    epilepticus in another. About half of patients have pharmacoresistant
    seizures, and no disease-modifying therapy exists.
  treatment_term:
    preferred_term: Pharmacotherapy
    term:
      id: NCIT:C15986
      label: Pharmacotherapy
    therapeutic_agent:
    - preferred_term: valproic acid
      term:
        id: CHEBI:39867
        label: valproic acid
    - preferred_term: levetiracetam
      term:
        id: CHEBI:6437
        label: levetiracetam
    - preferred_term: zonisamide
      term:
        id: CHEBI:10127
        label: zonisamide
    - preferred_term: clobazam
      term:
        id: CHEBI:31413
        label: clobazam
    - preferred_term: piracetam
      term:
        id: CHEBI:32010
        label: Piracetam
  therapeutic_modality: SMALL_MOLECULE
  target_phenotypes:
  - preferred_term: Myoclonus
    term:
      id: HP:0001336
      label: Myoclonus
  - preferred_term: Seizure
    term:
      id: HP:0001250
      label: Seizure
  notes: >-
    Evidence is limited to single case reports; there are no trials in this
    disorder.
  evidence:
  - reference: PMID:34092044
    reference_title: "Zonisamide-responsive myoclonus in SEMA6B-associated progressive myoclonic epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "In the present case, treatment with zonisamide caused clinical improvement, particularly of positive and negative truncal myoclonus, considerably improving patient's gait and thus mobility."
    explanation: >-
      Single-patient report of zonisamide improving myoclonus and mobility.
  - reference: PMID:35573939
    reference_title: "Non-convulsive Status Epilepticus in SEMA6B-Related Progressive Myoclonic Epilepsy: A Case Report With Literature Review."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Notably, NCSE was controlled by a combination of piracetam with clobazam and valproic acid instead of intravenous infusion of midazolam and phenobarbital."
    explanation: >-
      Single-patient report of a drug combination ending non-convulsive status
      epilepticus.
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Treatment with VPA allowed complete seizure freedom."
    explanation: >-
      Valproate gave seizure freedom in one patient of the series.
prevalence:
- population: Worldwide (published case reports)
  measure_type: CASES_IN_LITERATURE
  notes: >-
    No population estimate exists. A 2025 systematic review collected 36
    reported patients from 12 studies, of whom 18 had progressive myoclonus
    epilepsy, 13 developmental and epileptic encephalopathy, 4 a
    neurodevelopmental disorder without epilepsy and 1 epilepsy alone.
  evidence:
  - reference: PMID:39419291
    reference_title: "Progressive Myoclonus Epilepsy and Beyond: A Systematic Review of SEMA6B-related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "Patients were divided into four different phenotypic groups according to their clinical presentations: PME (18/36), developmental and epileptic encephalopathy (13/36), neurodevelopmental disorder (4/36), and epilepsy (1/36), respectively."
    explanation: >-
      Number and phenotypic distribution of reported patients.
animal_models:
- name: Zebrafish sema6ba/sema6bb exon 17 F0 crispants
  species: Zebrafish
  genotype: >-
    Mosaic F0 CRISPR-Cas9 crispants carrying frameshifts in the last coding
    exon (exon 17) of sema6ba, sema6bb or both, compared with crispants
    targeting the start codon in exon 2
  publication: PMID:32169168
  description: >-
    The only in vivo model of the disease variant class. Embryos with
    last-exon truncations of the sema6b orthologs had small heads, short bodies
    and a smaller optic tectum, and larvae showed exaggerated responses to the
    convulsant pentylenetetrazole; crispants targeting the start codon had a
    much milder phenotype. No spontaneous seizures were reported, and the
    animals were mosaic first-generation crispants rather than stable
    heterozygous lines.
  modeled_mechanisms:
  - target: Abnormal Neural Circuit Development
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      Last-exon truncation disturbs brain development more than start-codon
      disruption, mirroring the position dependence of the human variants.
    limitations: >-
      Mosaic F0 crispants with an unknown allele mix and dosage, in a species
      with two sema6b paralogs; the defects measured (head size, optic tectum
      area) are gross morphology rather than circuit wiring, and stable
      heterozygous lines were not studied.
    model_scale: TISSUE
    evidence:
    - reference: PMID:32169168
      reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "ICD truncation, therefore, produces more significant CNS anomalies than the loss-of-function in a zebrafish model."
      explanation: >-
        The model's central finding on position-dependent severity.
    - reference: PMID:32169168
      reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Because F0 crispants are mosaic, to more closely resemble the pathological conditions of the NMD(−) variants in humans, we would need to establish F1 generations and perform the correct crosses of zebrafish."
      explanation: >-
        The authors' own statement of the model's main limitation.
  - target: Cortical Hyperexcitability
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      Larvae with last-exon truncations show heightened seizure-like behaviour
      after pentylenetetrazole exposure.
    limitations: >-
      Seizure behaviour was only provoked, not spontaneous, and zebrafish
      larvae have no cerebral cortex, so the readout is a whole-larva
      excitability measure rather than cortical hyperexcitability.
    model_scale: ORGANISM
    readouts:
    - name: Pentylenetetrazole-induced swimming activity and convulsive behaviour
      target: Cortical Hyperexcitability
      direction: INCREASED
      interpretation: >-
        Provoked seizure susceptibility, increased in exon 17 crispants relative
        to exon 2 crispants.
      evidence:
      - reference: PMID:32169168
        reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
        supports: SUPPORT
        evidence_source: MODEL_ORGANISM
        snippet: "Our zebrafish sema6ba/b-ex.17-injected crispants demonstrated increased PTZ-mediated hyperactive responses compared with the response of the sema6ba/b-ex.2-injected larvae."
        explanation: >-
          The measured provoked-seizure readout.
    evidence:
    - reference: PMID:32169168
      reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "Seizure behavior was not observed in any larvae that were not treated with PTZ"
      explanation: >-
        Without the convulsant no seizure behaviour was seen, so the model shows
        increased susceptibility rather than spontaneous epilepsy.
- name: Sema6b-deficient mouse
  species: Mouse
  genotype: Sema6b knockout
  publication: PMID:20484647
  description: >-
    A null allele, not the human variant class. It shows that loss of Sema6b
    misroutes hippocampal mossy fibres, which supports a role for SEMA6B in
    mammalian brain wiring; no seizure or behavioural phenotype relevant to
    EPM11 is reported in the cited study.
  modeled_mechanisms:
  - target: Defective Axon Guidance
    relationship: PARTIALLY_RECAPITULATES
    fidelity: LOW
    description: >-
      Complete loss of Sema6b disturbs lamina-specific axon targeting in the
      hippocampus.
    limitations: >-
      A homozygous null rather than a heterozygous last-exon truncation, so it
      tests loss of SEMA6B rather than the truncated protein made in patients.
    evidence:
    - reference: PMID:20484647
      reference_title: "Roles of semaphorin-6B and plexin-A2 in lamina-restricted projection of hippocampal mossy fibers."
      supports: SUPPORT
      evidence_source: MODEL_ORGANISM
      snippet: "In Sema6B-deficient mice several mossy fibers aberrantly project to the stratum radiatum and the stratum oriens."
      explanation: >-
        Axon misrouting in the Sema6b-null hippocampus.
discussions:
- discussion_id: sema6b_truncation_mechanism
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    Do last-exon SEMA6B truncations cause disease by a dominant-negative
    effect on wild-type SEMA6B, by a new toxic function of the truncated
    protein, or by loss of function of the mutant allele that population data
    say is not sufficient on its own?
  attaches_to:
  - pathophysiology#SEMA6B Last-Exon Truncating Variant Escaping NMD
  - pathophysiology#Stable Truncated SEMA6B Lacking the Intracellular Domain
  - pathophysiology#Disrupted SEMA6B-Plexin Signalling
  rationale: >-
    The discovery study inferred a dominant-negative or gain-of-function
    mechanism from three facts: the variants escape decay, upstream truncating
    variants are tolerated, and zebrafish last-exon crispants were more severely
    affected than start-codon crispants. Later papers state the mechanism in
    different directions: one review calls it a toxic gain of function, while
    the neuronal study calls the tested variant loss-of-function and found that
    knockdown of wild-type Sema6b reproduced the spine defect. The truncated
    protein is overexpressed and mislocalized in transfected cells, which fits
    either retention of wild-type partners or a new activity. None of the
    experiments tested the variant at physiological heterozygous dosage in a
    mammalian neuron, and the zebrafish crispants were mosaic, so the field
    has a consistent observation (position matters) without a demonstrated
    mechanism. This is why functional_impact_category is UNKNOWN.
  proposed_experiments:
  - experiment_id: sema6b_heterozygous_knockin_vs_null
    experiment_design: TARGETED_PERTURBATION
    name: Heterozygous exon 17 truncation knock-in compared with a heterozygous null
    description: >-
      Generate mice or human iPSC-derived cortical neurons heterozygous for a
      recurrent exon 17 truncation, and in parallel heterozygous and homozygous
      null alleles, then compare spine density, axon targeting, network
      excitability and, in mice, seizure susceptibility. Co-express wild-type
      and truncated SEMA6B to test whether the truncated protein retains
      wild-type SEMA6B or plexin-A2 intracellularly.
    would_support:
    - pathophysiology#Disrupted SEMA6B-Plexin Signalling
    supporting_outcome:
    - >-
      The heterozygous knock-in has a phenotype that the heterozygous null
      lacks, and the truncated protein retains wild-type SEMA6B or plexin-A2
      away from the membrane, favouring a dominant-negative effect.
    refuting_outcome:
    - >-
      Heterozygous knock-in and heterozygous null neurons are indistinguishable,
      which would argue against a dominant mechanism of the truncated protein.
  evidence:
  - reference: PMID:32169168
    reference_title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Collectively, these results indicate that the pathomechanism of truncating DNVs in the NMD(−) region of SEMA6B was most likely dominant-negative or gain-of-function, but not haploinsufficiency."
    explanation: >-
      The discovery study's inference, which names two mechanisms without
      choosing between them.
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: BACKGROUND
    snippet: "The exon 17 is mainly involved, with truncating mutations causing the production of aberrant proteins with toxic gain of function."
    explanation: >-
      A later clinical series states a toxic gain of function as if settled,
      without new functional data.
  - reference: PMID:35604360
    reference_title: "SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance."
    supports: SUPPORT
    evidence_source: IN_VITRO
    snippet: "This study confirms that loss-of-function variants in the last exon confer pathogenicity and shows that missense mutations also exert deleterious effects."
    explanation: >-
      The neuronal study describes the same variant class as loss-of-function,
      the opposite framing.
- discussion_id: sema6b_spectrum_lump
  kind: INTERPRETATION
  status: OPEN
  prompt: >-
    Are SEMA6B-related developmental and epileptic encephalopathy and
    intellectual disability without epilepsy the same disease as EPM11?
  attaches_to:
  - disease#Progressive Myoclonic Epilepsy Type 11
  rationale: >-
    This entry lumps them. All presentations arise from the same heterozygous
    de novo variants, mostly the same exon 17 truncations, and recurrent
    variants appear in patients classed in different groups. No genotype
    correlates with the progressive myoclonic versus encephalopathy
    presentation, MONDO and OMIM carry only the EPM11 concept, and several
    patients first diagnosed with an encephalopathy later developed the
    progressive myoclonic course. Age at last examination may explain part of
    the difference, since progressive myoclonus usually becomes evident in the
    second decade. The lump should be revisited if a genotype-phenotype
    correlation emerges or if missense variants prove to cause a distinct
    disorder.
  evidence:
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Moreover, by the revision of literature, severity does not clearly correlate with genotype, and patients with the same genetic alteration could present different phenotypes."
    explanation: >-
      The same variant can produce different presentations, which argues for a
      single disease spectrum.
  - reference: PMID:39419291
    reference_title: "Progressive Myoclonus Epilepsy and Beyond: A Systematic Review of SEMA6B-related Disorders."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    quote_role: REVIEW_SYNTHESIS
    snippet: "In conclusion, although SEMA6B has been associated with PME, it may actually cause a much broader phenotypic spectrum."
    explanation: >-
      Systematic review conclusion that SEMA6B disease is a spectrum broader
      than PME.
- discussion_id: sema6b_progression_mechanism
  kind: KNOWLEDGE_GAP
  status: OPEN
  prompt: >-
    What drives the regression in EPM11: ongoing neurodegeneration, the
    cumulative effect of seizures and myoclonus, or a developmental lesion
    that becomes symptomatic with age?
  attaches_to:
  - phenotypes#Developmental Regression
  - phenotypes#Loss of Speech
  - phenotypes#Spasticity
  rationale: >-
    Patients lose motor and language skills, often in the second decade, yet
    brain MRI is normal in most and neither neuropathology nor a model has
    shown neuronal loss. One appraisal attributes motor regression partly to
    worsening myoclonus, and treating myoclonus improved gait in one patient,
    but cognitive regression and pyramidal signs have no explanation. These
    phenotypes are therefore left without a causal edge in this entry.
  evidence:
  - reference: PMID:36719163
    reference_title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
    supports: SUPPORT
    evidence_source: HUMAN_CLINICAL
    snippet: "Repeated MRIs (from the age of 3 to 25 years) were normal."
    explanation: >-
      Normal serial imaging despite severe regression in one patient.
references:
- reference: PMID:32169168
  title: "De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy."
- reference: PMID:36719163
  title: "Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes."
- reference: PMID:39419291
  title: "Progressive Myoclonus Epilepsy and Beyond: A Systematic Review of SEMA6B-related Disorders."
📚

References & Deep Research

References

3
PMID:32169168
De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy.
No top-level findings curated for this source.
PMID:36719163
Progressive myoclonus epilepsies due to SEMA6B mutations. New variants and appraisal of published phenotypes.
No top-level findings curated for this source.
PMID:39419291
Progressive Myoclonus Epilepsy and Beyond: A Systematic Review of SEMA6B-related Disorders.
No top-level findings curated for this source.

Deep Research

1

Deep research results are used as seeds for research; they do not undergo the same validation as the main records and may contain errors. How we use deep research.

Evaluations and curation notes (1)

Create: Progressive_Myoclonic_Epilepsy_Type_11 · 2026-10-20T19:42:38Z · View source

New entry for EPM11 (MONDO:0030034), caused by heterozygous, mostly de novo, truncating SEMA6B variants in exon 17 that escape nonsense-mediated decay. Curated from primary literature fetched from PubMed (Hamanaka 2020 discovery study with zebrafish crispants; Courage 2021 replication; Xiaozhen 2021 and Cordovado 2022 functional studies; Castellotti 2023 phenotype appraisal; Altintas 2025 systematic review; case reports for treatment and status epilepticus; Torene 2024 NMD-escape enrichment) plus the ClinGen gene-disease validity record. The OpenScientist deep-research report (research/Progressive_Myoclonic_Epilepsy_Type_11-deep-research-openscientist.md) was read and used as a cross-check; all 12 of its references resolved. Dropped from it: the SEMA6B identifier HGNC:7357 and chromosome 15q21.1 (both wrong; the gene is hgnc:10739 on 19p13.3), seven mislabelled HP and NCIT terms flagged by its own term validation, its statement that a toxic gain-of-function or dominant-negative mechanism is directly supported, the excitation-inhibition and GABAergic interneuron branch (no SEMA6B-specific evidence), and treatment recommendations extrapolated from other progressive myoclonus epilepsies (Unverricht-Lundborg, MERRF, GOSR2 Drosophila), which are not evidence for this disease. Scope decisions: developmental and epileptic encephalopathy and intellectual disability without epilepsy caused by the same variants are treated as one SEMA6B-related spectrum within this entry (recorded as an INTERPRETATION discussion); the variant mechanism is left as functional_impact_category UNKNOWN with a KNOWLEDGE_GAP discussion, because the literature describes the same variant class as dominant-negative, toxic gain-of-function and loss-of-function without a mammalian test at heterozygous dosage. ClinGen's Definitive AD classification is filed against the parent class MONDO:0020074, so it is cited as evidence but not recorded in gene_disease_validity. No GeneReviews chapter exists (check-genereviews --online). preflight-dr could not run without a local mondo.db; entity identity was checked by hand. Regression, loss of speech and spasticity are left without a causal edge because no source explains their mechanism; this is recorded as a second KNOWLEDGE_GAP.

OpenScientist ▸
Progressive Myoclonic Epilepsy Type 11 (EPM11): A Comprehensive Disease Characteristics Report
openscientist-autonomous 12 citations 2026-10-20T19:32:07.237255

Progressive Myoclonic Epilepsy Type 11 (EPM11): A Comprehensive Disease Characteristics Report

Disease: Progressive Myoclonic Epilepsy Type 11 (EPM11) MONDO ID: MONDO:0030034 · OMIM: #618876 · Causal gene: SEMA6B (HGNC:7357) Category: Mendelian (monogenic), autosomal dominant

Summary

Progressive Myoclonic Epilepsy Type 11 (EPM11) is an ultra-rare, autosomal-dominant progressive myoclonic epilepsy / developmental-and-epileptic-encephalopathy caused by heterozygous, usually de novo, truncating variants clustered in the last exon (exon 17) of SEMA6B (semaphorin-6B). The defining molecular feature is that these variants fall within the nonsense-mediated mRNA decay (NMD)-insensitive region of the transcript. Rather than being degraded, the mutant mRNA is translated into a stable truncated protein lacking the intracellular domain, which acts through a toxic gain-of-function / dominant-negative mechanism. This distinguishes EPM11 from simple haploinsufficiency disorders and explains why the de novo truncating variant class is so tightly disease-associated (PMID: 32169168; PMID: 36719163).

Mechanistically, SEMA6B is a transmembrane class-6 semaphorin that functions as an axon-guidance receptor binding floorplate-derived PlexinA2 (and, in hippocampal mossy fibers, PlexinA4). The intracellular domain lost in disease truncations is essential for its receptor-signaling function. Disruption of SEMA6B signaling impairs axon guidance, dendritic-spine maturation, and synaptogenesis across cortical, hippocampal, and cerebellar circuits—including GABAergic interneurons—producing an excitation/inhibition imbalance that drives cortical hyperexcitability, seizures, and myoclonus, alongside developmental regression, intellectual disability, and ataxia (PMID: 25209245; PMID: 35604360; PMID: 20484647).

Clinically, EPM11 typically presents with developmental regression around age 2 after relatively normal early development, followed by polymorphic and often refractory seizures, progressive myoclonus, ataxia, spasticity, loss of independent ambulation, and severe cognitive impairment. The known worldwide caseload is tiny—approximately 36 reported patients—spanning a phenotypic spectrum from classic PME to non-syndromic intellectual disability. There is no disease-modifying or curative therapy; management is symptomatic anti-seizure/anti-myoclonic polytherapy with supportive care, and prognosis is poor with lifelong, progressive disability (PMID: 39419291; PMID: 30999254).

1. Disease Information

Overview. EPM11 is a monogenic progressive myoclonic epilepsy (PME) belonging to the group of developmental and epileptic encephalopathies. It is characterized by infantile/early-childhood onset, developmental regression, progressive myoclonus, polymorphic and frequently pharmacoresistant seizures, cerebellar and pyramidal/extrapyramidal signs, and severe cognitive impairment.

Key identifiers:

Resource Identifier
OMIM #618876 (Epilepsy, progressive myoclonic, 11)
MONDO MONDO:0030034
Gene SEMA6B (HGNC:7357); OMIM gene *608873
Inheritance Autosomal dominant (ClinGen gene–disease validity: Definitive)
ICD-11 8A62 (Progressive myoclonic epilepsy) category
MeSH Myoclonic Epilepsies, Progressive (D020191)

Synonyms / alternative names: EPM11; SEMA6B-related progressive myoclonic epilepsy; SEMA6B-related developmental and epileptic encephalopathy; progressive myoclonic epilepsy-11.

Source of information. Information is derived from aggregated disease-level resources (OMIM, Orphanet, ClinGen) and from individual patient case reports and small case series in the primary literature, rather than from large EHR cohorts. Given the extreme rarity, the evidence base is dominated by case-level descriptions.

2. Etiology

Primary cause — genetic. EPM11 is a purely monogenic disorder caused by heterozygous pathogenic variants in SEMA6B. The predominant and best-validated class is truncating (frameshift/nonsense) variants clustered in the last exon (exon 17), which escape NMD and produce a toxic truncated protein (PMID: 32169168; PMID: 36719163).

Genetic risk factors. The causal variants are themselves the disease determinant. Most arise de novo; variants are absent from population databases such as gnomAD, consistent with pathogenicity. No susceptibility loci or modifier genes have been established.

Environmental risk factors. None implicated. No toxic, infectious, lifestyle, occupational, dietary, radiation, or age/sex-related environmental risk factors are known to contribute. EPM11 is not triggered by environmental exposure.

Protective factors. No genetic or environmental protective factors or modifier alleles are known. The only outcome-modifying factor identified is effective seizure control (see Prognosis).

Gene–environment interactions. None known; as a Mendelian disorder with high penetrance of the classic truncating variants, no GxE interactions have been characterized.

3. Phenotypes

EPM11 is a multi-domain neurological disorder. Core phenotypes and suggested HPO terms:

Phenotype HPO term (suggested) Type Onset Progression Frequency
Myoclonic seizures / myoclonus HP:0001336 / HP:0001337 Clinical sign Early childhood Progressive, worsening Core / near-universal
Progressive myoclonic epilepsy HP:0007334 Clinical syndrome ~18 mo–6 yr Progressive 50% of spectrum (18/36)
Developmental regression HP:0002376 Sign ~2 yr Progressive Common
Intellectual disability (severe) HP:0010864 Sign Childhood Progressive Severe; often nonverbal
Polymorphic seizures (atonic, absence, focal, GTCS, negative myoclonus) HP:0002197, HP:0002121, HP:0002384, HP:0002069 Clinical sign 18 mo–6 yr Refractory in ~50% Core
Ataxia / cerebellar signs HP:0001251 Sign 1st–2nd decade Progressive Common
Spasticity / pyramidal signs HP:0001257 Sign 1st–2nd decade Progressive Common
Tremor HP:0001337 Sign 1st–2nd decade Progressive Common
Loss of ambulation HP:0002540 Functional 1st–2nd decade Progressive Frequent
Non-convulsive status epilepticus HP:0011146 Clinical sign Variable Episodic Reported

Phenotype characteristics. Onset of developmental regression occurs around 2 years of age after relatively normal early development; various seizure types emerge between 18 months and 6 years and are often refractory. Over the first and second decades, pyramidal, extrapyramidal, and cerebellar signs accumulate. Cognitive impairment is severe (few words or non-verbal). The phenotype is progressive and does not correlate with variant type or location (PMID: 32169168; PMID: 36719163; PMID: 35604360).

Phenotypic spectrum. Cordovado et al. (2022) showed the spectrum extends beyond classic PME: "until now, SEMA6B variants have mainly been reported in patients with progressive myoclonic epilepsy, our study indicates that the clinical spectrum is wider and also includes non-syndromic ID without epilepsy or myoclonus" (PMID: 35604360). The 2025 systematic review (n=36) subdivided presentations into PME (50%, 18/36), developmental and epileptic encephalopathy (36%, 13/36), neurodevelopmental disorder (11%, 4/36), and epilepsy (3%, 1/36) (PMID: 39419291).

Quality of life impact. Severe. Progressive loss of ambulation, non-verbal status, refractory seizures, and myoclonus produce profound dependence in daily functioning and lifelong disability. EPM11 can clinically mimic Angelman syndrome (PMID: 42125992).

4. Genetic / Molecular Information

Causal gene. SEMA6B (semaphorin-6B), HGNC:7357, located on chromosome 15q21.1, encoding a transmembrane class-6 semaphorin. UniProt: Q9H3T3.

Pathogenic variants. - Predominant class: Truncating (frameshift and nonsense) variants clustered in the last exon (exon 17), which fall in the NMD-insensitive region. These escape nonsense-mediated decay and produce a stable protein lacking the intracellular domain (PMID: 32169168; PMID: 36719163). - Rarer classes: Missense variants (e.g., c.432C>G p.Cys144Trp, reported in an adult-onset case) and non-last-exon splice-site variants (e.g., c.1680-2A>G, NM_032108.4) producing diverse aberrant transcripts with incomplete penetrance (PMID: 42696975).

Variant classification (ACMG/AMP). Recurrent de novo exon-17 truncating variants are classified pathogenic/likely pathogenic, supported by genome-wide statistical enrichment in developmental and epileptic encephalopathy trios and absence from population databases.

Allele frequency. The causal de novo variants are absent from gnomAD and other population databases, consistent with pathogenicity.

Somatic vs germline. Variants are germline (constitutional), usually de novo; rare inherited (autosomal-dominant transmitted) cases exist.

Functional consequences. Gain of function / dominant-negative. Castellotti et al. state: "The exon 17 is mainly involved, with truncating mutations causing the production of aberrant proteins with toxic gain of function" (PMID: 36719163). The truncated protein lacks the intracellular domain required for receptor signaling and mislocalizes subcellularly, reducing dendritic spine maturation (PMID: 35604360).

Modifier genes / epigenetics / chromosomal abnormalities. None established. No DNA methylation or histone-modification changes have been characterized for EPM11, and no large-scale chromosomal rearrangements are implicated (though a 12p13.32 deletion appears in the broader PMA differential, unrelated to SEMA6B).

5. Environmental Information

Not applicable. EPM11 is a monogenic disorder with no identified environmental, lifestyle, toxic, occupational, radiation, or infectious contributing factors. No infectious agents trigger or cause the disease.

6. Mechanism / Pathophysiology

Ordered causal chain

  1. A de novo (usually) truncating variant in the last exon (exon 17) of SEMA6B arises → leads to a premature stop codon in the NMD-insensitive region.
  2. Because the variant lies in the NMD(-) region, the mutant mRNA escapes nonsense-mediated decay → results in a stable truncated SEMA6B protein lacking the intracellular domain (inferred from NMD rules + observed protein; demonstrated in overexpression systems).
  3. The truncated protein exerts a dominant-negative / toxic gain-of-function effect on SEMA6B signaling (and mislocalizes subcellularly) → results in disrupted SEMA6B–PlexinA2 (and PlexinA4) receptor signaling.
  4. Disrupted semaphorin–plexin signaling → leads to impaired axon guidance, reduced dendritic-spine density/maturation, and defective synaptogenesis.
  5. Faulty wiring across cortical, hippocampal (mossy fiber), and cerebellar circuits, including GABAergic interneurons → results in abnormal neural connectivity. The mechanism branches here:
  6. Branch 6a (epileptogenesis): reduced inhibition / excitation–inhibition imbalance → cortical hyperexcitability → myoclonus, polymorphic and refractory seizures.
  7. Branch 6b (neurodevelopmental): abnormal connectivity and ongoing circuit dysfunction → developmental regression, severe intellectual disability, ataxia, and progressive pyramidal/extrapyramidal signs.
  8. Progressive accumulation of circuit dysfunction over the first two decades → leads to loss of ambulation, non-verbal status, and lifelong disability.

(Steps 1–3 and the gain-of-function nature are directly supported; the GABAergic/E-I-imbalance link in branch 6a is partly inferred from expression data and general PME pathophysiology.)

Supporting detail

  • Molecular pathways: Semaphorin–plexin axon-guidance signaling. SEMA6B binds PlexinA2 at the midline and PlexinA4 in the hippocampus. GO:0007411 (axon guidance); GO:0071526 (semaphorin-plexin signaling pathway). "we demonstrate that Sema6B binds to floorplate-derived plexin A2 (PlxnA2) for navigation at the midline" (PMID: 25209245).
  • Protein dysfunction: Loss of the intracellular domain abolishes receptor signaling: "Truncated Sema6B lacking the intracellular domain was unable to rescue the loss-of-function phenotype, confirming a receptor function of Sema6B" (PMID: 25209245). Patient variants mislocalize and reduce spine density: "The overexpression of some variants leads to a subcellular mislocalization of SEMA6B protein in HEK293T cells and to a reduced spine density owing to loss of mature spines in neuronal cultures" (PMID: 35604360).
  • Cellular processes: Dendritic spine formation/maturation (GO:0060996, GO:0060997), synaptogenesis, neuronal migration/wiring. Cell types: cortical excitatory neurons (CL:0000679), GABAergic inhibitory interneurons (CL:0000617), cerebellar Purkinje cells (CL:0000121), hippocampal pyramidal neurons.
  • Subcellular compartments: Plasma membrane (transmembrane receptor), dendritic spine, axonal growth cone; disease-associated mislocalization.
  • Metabolic / immune involvement: None characterized; EPM11 is not a metabolic or immune-mediated PME.
  • Omics profiling: No disease-specific transcriptomic, proteomic, metabolomic, or lipidomic signatures have been published; mechanistic data derive from targeted functional assays.

7. Anatomical Structures Affected

Organ / system level. Primary involvement is the central nervous system (UBERON:0001017). Key regions: cerebral cortex (UBERON:0000956), cerebellum (UBERON:0002037, Purkinje cells), hippocampus (UBERON:0002421, mossy fiber projections). Body system: nervous system (UBERON:0001016). No primary non-neurological organ involvement; secondary effects (e.g., immobility-related complications) follow from progressive disability.

Tissue / cell level. Nervous tissue. Affected cell populations: cortical excitatory neurons (CL:0000679), GABAergic interneurons (CL:0000617), cerebellar Purkinje cells (CL:0000121), hippocampal neurons. SEMA6B is highly expressed across these neuronal populations.

Subcellular level. Plasma membrane / transmembrane receptor localization; dendritic spines; axonal growth cones. GO cellular components: GO:0005886 (plasma membrane), GO:0043197 (dendritic spine).

Localization / lateralization. Diffuse, bilateral CNS involvement. EEG shows focal, multifocal, and diffuse abnormalities (see Diagnostics); brain MRI is often normal or non-specific.

8. Temporal Development

  • Onset: Developmental regression around age 2 after relatively normal early development; insidious/subacute onset. Seizures emerge between 18 months and 6 years. A rare adult-onset missense case exists.
  • Progression: Chronic and progressive. Over the first and second decades, pyramidal, extrapyramidal, and cerebellar signs worsen (spasticity, loss of ambulation, myoclonus, tremor, ataxia). Seizures frequently refractory (~50% pharmacoresistant). Course is lifelong.
  • Stages: Early (regression + seizure onset) → intermediate (progressive myoclonus, motor decline) → advanced (loss of ambulation, non-verbal, severe disability).
  • Patterns: No spontaneous remission; seizures episodic but underlying neurodegeneration is relentlessly progressive. The critical window for intervention is early seizure control, which is associated with improved neurodevelopmental outcomes (PMID: 42696975).

9. Inheritance and Population

  • Epidemiology: Ultra-rare. Only ~36 patients reported worldwide (2025 systematic review); no prevalence/incidence estimates exist (PMID: 39419291).
  • Inheritance: Autosomal dominant, mostly de novo. ClinGen gene–disease validity Definitive. Rare inherited (AD-transmitted) families exist.
  • Penetrance: High/complete for classic exon-17 truncating variants; incomplete penetrance documented for a splice-site variant family (c.1680-2A>G) — "a novel heterozygous donor splice-site variant NM_032108.4 (SEMA6B): c.1680-2A>G segregating with autosomal dominant EPM1 in a family exhibiting marked incomplete penetrance" (PMID: 42696975).
  • Expressivity: Variable (PME to non-syndromic ID), not correlated with variant type/location.
  • Anticipation / mosaicism / founder effects / consanguinity: No genetic anticipation (not a repeat-expansion disorder); germline mosaicism theoretically possible but not systematically documented; no founder effect or geographic clustering. The original 4 patients were ethnically diverse (2 Japanese, 1 Israeli, 1 Malaysian).
  • Carrier frequency: Not applicable for a mostly de novo, dominant disorder.
  • Sex ratio / age distribution: No sex predilection reported; affected individuals are predominantly children and young adults.

10. Diagnostics

Diagnostic approach — genetic. Diagnosis relies on molecular genetic testing: exome (WES) or genome sequencing (WGS), or a multigene epilepsy/PME panel detecting the heterozygous SEMA6B truncating variant (typically exon 17, usually de novo). There is no specific biochemical biomarker, and brain MRI is often normal or non-specific (PMID: 32169168).

Test Utility in EPM11
WES / WGS High — primary diagnostic modality
Epilepsy / PME multigene panel High — SEMA6B now included on PME panels
Single-gene SEMA6B sequencing Useful if phenotype strongly suggestive
EEG Supportive — focal/multifocal spikes, diffuse irregular spike-wave, high-amplitude slow waves
Brain MRI Often normal/non-specific; used to exclude other causes
Biochemical/metabolic biomarkers Not informative (no metabolic signature)
CMA/karyotype/FISH Low yield (not a copy-number/structural disorder)
mtDNA / repeat-expansion testing Used to exclude PME mimics (e.g., MERRF, EPM1), not positive in EPM11

Clinical criteria & differential diagnosis. Diagnosis integrates the PME clinical syndrome with a confirmatory SEMA6B variant. Differential diagnosis includes other PMEs (Unverricht-Lundborg disease/EPM1, Lafora disease, MERRF, neuronal ceroid lipofuscinoses, sialidosis, North Sea PME/GOSR2) and Angelman syndrome, which EPM11 can mimic (PMID: 42125992). Progressive myoclonus ataxia (PMA) overlaps on a PMA-PME spectrum (PMID: 38844245).

Screening. No population newborn or carrier screening exists (ultra-rare, mostly de novo). Cascade testing is only relevant in the rare inherited families.

11. Outcome / Prognosis

Prognosis is poor. EPM11 is a progressive neurodegenerative disorder (OMIM #618876). Over the first and second decades, affected individuals develop worsening pyramidal, extrapyramidal, and cerebellar signs—spasticity, loss of independent ambulation, myoclonus, tremor, ataxia—and severe cognitive impairment, becoming non-verbal (PMID: 32169168). Seizures are frequently refractory/pharmacoresistant (~half of 36 patients) (PMID: 39419291).

  • Survival/mortality: Specific survival and mortality statistics are not established given extreme rarity.
  • Morbidity/disability: Severe, progressive, lifelong. Quality of life severely impaired.
  • Recovery potential: None; the disorder does not remit and disability accumulates.
  • Prognostic factors: The principal modifiable factor is seizure control — "effective anti-seizure medication was associated with improved neurodevelopmental outcomes" (PMID: 42696975).
  • Prognostic biomarkers: None validated. Cortical hyperexcitability (giant SEPs / EMG-EEG correlate of myoclonus) may have prognostic value within the broader PMA-PME spectrum (PMID: 38844245).

12. Treatment

No disease-modifying or curative therapy exists. Management is symptomatic, centered on anti-seizure medications (ASMs), as for progressive myoclonus epilepsies generally (PMID: 32169168).

Pharmacotherapy (NCIT terms suggested):

Drug Class Role in PME/EPM11 NCIT
Valproic acid Broad-spectrum ASM Mainstay for GTCS and myoclonus NCIT:C935
Clonazepam Benzodiazepine Mainstay anti-myoclonic NCIT:C577
Levetiracetam SV2A modulator Effective add-on for myoclonus NCIT:C29102
Topiramate Broad-spectrum ASM Add-on option NCIT:C921

Lasek-Bal et al. describe the standard polytherapy strategy in PME: "ULD patients require anti-epileptic polytherapy, mostly benefitting from managing GTCS and myoclonus with valproic acid and clonazepam treatment. Patients may benefit from add-on therapy with levetiracetam or topiramate" (PMID: 30999254).

Drugs to avoid. Sodium-channel blockers (phenytoin, carbamazepine, lamotrigine, vigabatrin) can worsen myoclonus and are generally avoided in PME.

Emerging / cross-PME insights. In related PME models, GABA-ergic agents (sodium barbital, clonazepam, and the neurosteroid ganaxolone) suppressed seizures more effectively than valproate/levetiracetam in a GOSR2 North Sea PME Drosophila model, highlighting a potential GABA-targeted direction (PMID: 38781737). Combination levetiracetam + clonazepam is effective for myoclonus in MERRF (PMID: 30334528). These are extrapolations, not EPM11-specific trials.

Advanced/experimental therapeutics. No gene therapy, RNA-based therapy, cell therapy, or targeted molecular therapy exists or is in trials for EPM11. The toxic gain-of-function mechanism in principle makes allele-selective knockdown (ASO/siRNA) a theoretically rational—but currently unexplored—strategy.

Supportive/rehabilitative care. Physical, occupational, and speech therapy; management of spasticity, nutrition, and mobility; multidisciplinary neurological care.

13. Prevention

  • Primary prevention: Not possible for de novo disease. In rare inherited families, genetic counseling and reproductive options (preimplantation genetic testing, prenatal diagnosis) apply.
  • Secondary prevention: Early molecular diagnosis and early effective seizure control, which may improve neurodevelopmental outcomes (PMID: 42696975).
  • Tertiary prevention: Avoiding myoclonus-aggravating ASMs; managing complications of progressive disability.
  • Counseling: Genetic counseling is central—recurrence risk is low for confirmed de novo cases (with residual germline mosaicism risk) but up to 50% in autosomal-dominant transmitted families with variable/incomplete penetrance.
  • Immunization / public health / environmental interventions: Not applicable.

14. Other Species / Natural Disease

  • Taxonomy / orthologs: SEMA6B is conserved across vertebrates. Mouse Sema6b (NCBI Gene) and chick Sema6B orthologs have been functionally characterized.
  • Natural disease: No naturally occurring EPM11-equivalent disease has been described in companion animals or wildlife (no OMIA entry for a SEMA6B epilepsy phenotype).
  • Comparative biology: The axon-guidance function of SEMA6B is evolutionarily conserved—defined in mouse (hippocampal mossy fibers, PlexinA4-dependent) and chick (commissural axons, PlexinA2-dependent) (PMID: 20484647; PMID: 25209245).
  • Transmission / zoonotic potential: Not applicable (genetic, non-communicable).

15. Model Organisms

Model Type Key finding Relevance / limitation
Sema6b-null mouse Mammalian knockout Viable; aberrant hippocampal mossy fiber projections into stratum radiatum/oriens; additive with Sema6a Models loss-of-function, not the human gain-of-function mechanism (PMID: 20484647)
Chick commissural neurons In vivo RNAi/rescue SEMA6B acts as PlexinA2-binding axon-guidance receptor; intracellular domain essential Established receptor role; not a disease model (PMID: 25209245)
HEK293T overexpression In vitro Patient variants mislocalize subcellularly Variant functional assay (PMID: 35604360)
Primary neuronal culture (shRNA) In vitro Reduced dendritic spine density/maturation Links SEMA6B to synaptic pathology (PMID: 35604360)
Chick embryo rescue assay In vivo Patient variants fail to rescue commissural axon pathfinding Demonstrates variant pathogenicity (PMID: 35604360)

Tawarayama et al.: "In Sema6B-deficient mice several mossy fibers aberrantly project to the stratum radiatum and the stratum oriens. The number of aberrant mossy fibers is increased in Sema6A;Sema6B double knock-out mice, indicating that Sema6A and Sema6B function additively to regulate proper projection of mossy fibers" (PMID: 20484647).

Key model limitation: Existing knockouts recapitulate the loss-of-function axon-guidance phenotype but do not model the dominant-negative/gain-of-function truncated protein that drives human EPM11. A knock-in mouse carrying a human exon-17 truncating variant is the most important missing model.

Mechanistic Model / Interpretation

 de novo SEMA6B exon-17 truncating variant (NMD-insensitive region)
      │  escapes nonsense-mediated decay
      ▼
   Stable truncated SEMA6B protein (lacks intracellular domain)
      │  dominant-negative / toxic gain-of-function
      ▼
   Disrupted SEMA6B–PlexinA2 / PlexinA4 receptor signaling
      │  (intracellular domain required for signaling)
      ▼
   Impaired axon guidance + reduced dendritic spine maturation + defective synaptogenesis
      │
┌─────────────┴──────────────┐
▼                            ▼
 Aberrant GABAergic/excitatory     Abnormal cortical/hippocampal/
 cortical wiring → E/I imbalance   cerebellar connectivity
▼                            ▼
 Cortical hyperexcitability →      Developmental regression, severe ID,
 myoclonus, polymorphic            ataxia, pyramidal/extrapyramidal signs
 refractory seizures                        │
└─────────────┬──────────────┘
      ▼
   Progressive neurodegeneration → loss of ambulation, non-verbal,
   lifelong severe disability (poor prognosis)

The model's hinge is step 3: the loss of the intracellular domain abolishes SEMA6B receptor signaling (PMID: 25209245), while NMD escape ensures the toxic protein is actually produced (PMID: 32169168). Upstream events (variant → NMD escape → truncated protein) are genetic and well-demonstrated; downstream events (circuit mis-wiring → E/I imbalance → seizures) are supported by cellular/animal data but the specific GABAergic contribution to human epileptogenesis remains partly inferred.

Evidence Base

PMID Title (abridged) Evidence type Contribution
32169168 De Novo Truncating Variants in the Last Exon of SEMA6B Cause Progressive Myoclonic Epilepsy Human genetics (trio cohort) Defines disease; NMD escape; dominant-negative/GoF; original 4 patients
36719163 Progressive myoclonus epilepsies due to SEMA6B mutations Human clinical/genetic Exon-17 clustering; toxic GoF; core phenotype
35604360 SEMA6B variants cause intellectual disability and alter dendritic spine density and axon guidance Human + in vitro/in vivo functional Broad spectrum; spine density; mislocalization; chick rescue
25209245 Semaphorin 6B acts as a receptor in post-crossing commissural axon guidance Model (chick) Receptor role; PlexinA2 binding; intracellular domain essential
20484647 Roles of semaphorin-6B and plexin-A2 in hippocampal mossy fibers Model (mouse) KO phenotype; PlexinA4-dependent repulsion
39419291 Systematic Review of SEMA6B-related Disorders Human systematic review (n=36) Caseload, phenotypic subgroups, pharmacoresistance
42696975 Novel SEMA6B splice-site variant (c.1680-2A>G) Human genetics/family AD transmission; incomplete penetrance; ASM-outcome link
42125992 SEMA6B-Related PME Mimicking Angelman Syndrome Human case Differential diagnosis
30999254 Unverricht-Lundborg disease: seizure management Human clinical PME ASM polytherapy strategy
38844245 Natural history of progressive myoclonus ataxia Human cohort PMA-PME spectrum; cortical hyperexcitability prognostic value
38781737 ASMs and GABA in North Sea PME Model (Drosophila) GABA-targeted therapy direction (cross-PME)
30334528 Levetiracetam+clonazepam in MERRF Human clinical Combination anti-myoclonic efficacy (cross-PME)

Convergence vs. challenge. The genetic and functional lines of evidence converge strongly on the NMD-escape/gain-of-function model. The main internal tension is that the available animal models are loss-of-function knockouts, which demonstrate the gene's normal axon-guidance role but do not directly prove the toxic gain-of-function human mechanism—this is inferred from NMD biology, protein-domain rescue failure, and variant overexpression data.

Limitations and Knowledge Gaps

  1. Tiny evidence base (~36 patients). No epidemiological estimates (prevalence/incidence), no survival/mortality statistics, and limited natural-history data.
  2. Mechanism inferred, not fully demonstrated in vivo. No animal model expresses the human truncated gain-of-function protein; the dominant-negative mechanism is supported by overexpression and domain-deletion rescue data, not by an endogenous knock-in.
  3. GABAergic/E-I imbalance link is partly inferred. The specific contribution of SEMA6B dysfunction in GABAergic interneurons to human epileptogenesis has not been directly measured in patient tissue.
  4. No omics signatures. No disease-specific transcriptomic, proteomic, or metabolomic profiles exist for EPM11.
  5. No disease-specific therapy or trial. All treatment data are extrapolated from PME broadly; no NCT-registered EPM11 trial exists.
  6. Genotype–phenotype correlation is weak/absent, complicating prognostic counseling, and incomplete penetrance in non-last-exon variants adds uncertainty.

Proposed Follow-up Experiments / Actions

  1. Generate a knock-in mouse (or human iPSC-neuron/organoid) carrying a recurrent exon-17 truncating SEMA6B variant to directly test the dominant-negative/gain-of-function model and establish a translational model that recapitulates the human disease (not just loss of function).
  2. Characterize E/I balance and GABAergic interneuron wiring in patient-derived iPSC cortical organoids with electrophysiology/MEA to validate the cortical-hyperexcitability branch.
  3. Test allele-selective knockdown (ASO/siRNA) of the mutant truncated transcript as a mechanistically rational, disease-modifying strategy for a gain-of-function disorder.
  4. Screen GABA-targeted agents (e.g., ganaxolone, clonazepam) vs. standard ASMs in an EPM11-specific model, building on cross-PME findings (PMID: 38781737).
  5. Establish an international patient registry to capture natural history, seizure-control-vs-outcome relationships, survival, and genotype–phenotype data.
  6. Systematic cortical-hyperexcitability phenotyping (giant SEPs, EMG-EEG) across the SEMA6B PMA-PME spectrum to develop prognostic biomarkers.

Report compiled from 11 confirmed findings across 5 investigation iterations and 14 reviewed primary papers. Evidence source types are indicated throughout: human clinical/genetic, model organism (mouse, chick, Drosophila), and in vitro functional.

Artifacts

Reference Validation

Checked with linkml-reference-validator 0.3.0.

Outcome Count
References checked 12
Resolved 12
Unresolved (possible confabulation) 0
Unverifiable 0
References weighed for topical relevance 12
On topic 7
Off topic 0

All extracted references resolved successfully.

Term Validation

Checked with linkml-term-validator 0.4.5, through the ols: adapter.

Outcome Count
Terms checked 33
Resolved 32
Unresolved (possible confabulation) 0
Obsolete 0
Unverifiable 1
Terms whose name was checked 20
Terms named correctly 10
Terms named as a different term 7
Terms whose name is worth a second look 3

Terms the report names something else

These identifiers resolve, so nothing about them looks wrong, and the ontology calls them something unrelated to what the report calls them. That usually means the identifier is not the one the sentence needs:

  • MONDO:0030034 (2 mentions) - the report calls it "MONDO"; MONDO calls it epilepsy, progressive myoclonic, 11
  • HP:0007334 (1 mention) - the report calls it "Progressive myoclonic epilepsy"; HP calls it Bilateral tonic-clonic seizure with focal onset
  • HP:0011146 (1 mention) - the report calls it "Non-convulsive status epilepticus"; HP calls it Dialeptic seizure
  • NCIT:C935 (1 mention) - the report calls it "Mainstay for GTCS and myoclonus"; NCIT calls it Vindesine Sulfate
  • NCIT:C577 (1 mention) - the report calls it "Mainstay anti-myoclonic"; NCIT calls it Industrial Waste
  • NCIT:C29102 (1 mention) - the report calls it "Effective add-on for myoclonus"; NCIT calls it Hydroxypropyl Methylcellulose D
  • NCIT:C921 (1 mention) - the report calls it "Add-on option"; NCIT calls it Uricosuric Agent

Terms whose name is worth a second look

The report's name for these is recognisably related to the term's own name without being one of them. A loose paraphrase reads the same way as a citation of the wrong sibling term - and so does a related synonym, which the ontology records precisely because it names something adjacent rather than the same thing - so these are listed rather than judged:

  • HP:0001251 (1 mention) - the report calls it "Ataxia / cerebellar signs"; HP calls it Ataxia, and lists "Cerebellar ataxia" among its other names
  • HP:0001257 (1 mention) - the report calls it "Spasticity / pyramidal signs"; HP calls it Spasticity
  • HP:0002540 (1 mention) - the report calls it "Loss of ambulation"; HP calls it Inability to walk, and lists "Non-ambulatory" among its other names